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Abstract
DETERMINANTS OF HIV-1 TRANSMISSION FITNESS
Shilpa S. Iyer
Beatrice H. Hahn
HIV-1 is predominantly transmitted by mucosal routes and almost 80 percent of new infections are initiated
by a single variant. The elucidation of the biological properties of transmitted viruses which distinguish them
from non-transmitted variants are critical for the development of therapeutic interventions. To identify such
properties, we characterized the biology of 300 limiting dilution-derived virus isolates from the plasma and
genital secretions of eight HIV-1 donor and recipient transmission pairs representing the most prevalent
subtypes (B and C). Recipient viruses were more infectious per viral particle as determined on a reporter cell
line, replicated to higher titers and were released more efficiently from infected primary CD4+ T cells than the
corresponding donor isolates. Recipient viruses were more resistant to the inhibitory effects of IFN-α2 and
IFN-β evidenced as higher half-maximal inhibitory concentrations and higher replication at the maximal
doses of IFN-α2 and IFN-β than corresponding donor isolates. Interestingly, pretreatment of CD4+ T cells
with IFN-β, but not IFN-α2 selected donor plasma isolates that exhibited phenotypes similar to transmitted
viruses. This suggests that transmitted variants are distinct and that the selective pressure imposed by type I
interferons may in part be responsible for the bottleneck associated with mucosal transmission. We next
wanted to assess the role of the interferon stimulated gene, tetherin in the antiviral state established by type I
IFNs. Thus, we introduced mutations into the vpu gene of various HIV-1 constructs to specifically disrupt
their Vpu-mediated tetherin antagonism, and determined the effect on replication and release from infected
cells in the presence and absence of IFN-α2. Mutations at key residues in Vpu reduced the viral particle
production and release from infected primary CD4+ T cells and this was particularly evident in IFN-
α2-treated cells. Interestingly, transmitted HIV-1 variants were released to higher levels from infected cells
than chronic control viruses, even in the absence of Vpu. Thus, the counteraction of tetherin resulting in
efficient particle release is an important determinant of the interferon resistance of mucosally transmitted
HIV-1.
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ABSTRACT 
 
DETERMINANTS OF HIV-1 TRANSMISSION FITNESS  
Shilpa S. Iyer 
Beatrice H. Hahn 
 
HIV-1 is predominantly transmitted by mucosal routes and almost 80 percent of new 
infections are initiated by a single variant. The elucidation of the biological properties of 
transmitted viruses which distinguish them from non-transmitted variants are critical for 
the development of therapeutic interventions. To identify such properties, we 
characterized the biology of 300 limiting dilution-derived virus isolates from the plasma 
and genital secretions of eight HIV-1 donor and recipient transmission pairs representing 
the most prevalent subtypes (B and C). Recipient viruses were more infectious per viral 
particle as determined on a reporter cell line, replicated to higher titers and were 
released more efficiently from infected primary CD4+ T cells than the corresponding 
donor isolates. Recipient viruses were more resistant to the inhibitory effects of IFN-α2 
and IFN-β evidenced as higher half-maximal inhibitory concentrations and higher 
replication at the maximal doses of IFN-α2 and IFN-β than corresponding donor isolates. 
Interestingly, pretreatment of CD4+ T cells with IFN-β, but not IFN-α2 selected donor 
plasma isolates that exhibited phenotypes similar to transmitted viruses. This suggests 
that transmitted variants are distinct and that the selective pressure imposed by type I 
interferons may in part be responsible for the bottleneck associated with mucosal 
transmission. We next wanted to assess the role of the interferon stimulated gene, 
tetherin in the antiviral state established by type I IFNs. Thus, we introduced mutations 
	 v	
into the vpu gene of various HIV-1 constructs to specifically disrupt their Vpu-mediated 
tetherin antagonism, and determined the effect on replication and release from infected 
cells in the presence and absence of IFN-α2. Mutations at key residues in Vpu reduced 
the viral particle production and release from infected primary CD4+ T cells and this was 
particularly evident in IFN-α2-treated cells. Interestingly, transmitted HIV-1 variants were 
released to higher levels from infected cells than chronic control viruses, even in the 
absence of Vpu. Thus, the counteraction of tetherin resulting in efficient particle release 
is an important determinant of the interferon resistance of mucosally transmitted HIV-1. 
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CHAPTER 1 
 
 
INTRODUCTION 
 
Shilpa S. Iyer 
 
Department of Medicine and Microbiology, Perelman School of Medicine at the 
University of Pennsylvania  
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Section 1.1 – Mucosal transmission of HIV-1 and the associated genetic 
bottleneck 
 
HIV-1 Epidemiology and Transmission Routes 
Human immunodeficiency virus type 1 (HIV-1) is a lentivirus and the causative agent of the 
Acquired Immunodeficiency Syndrome (AIDS). Phylogenetic analyses estimate that HIV-1 
entered the human population in the early 20th century (1). Since its introduction into the human 
population HIV-1 has infected over 70 million people (2)  and killed over 35 million. Despite 
widespread efforts to reduce transmission, 2 million people become infected by HIV-1 annually 
(2). HIV-1 is comprised of four groups – M (main), N (non-M, non-O), O (outlier) and P (3).  These 
groups are the result of 4 independent zoonotic transmissions of a simian immunodeficiency virus 
(SIV) to humans (3) with groups M and N derived from an SIV infecting chimpanzees (SIVcpz) (4) 
and groups O and P resulting from an SIV that infects gorillas (SIVgor) (5, 6). Group M accounts 
for the majority (99%) of all HIV-1 infected individuals worldwide (3, 7)  and, on the basis of 
genetic differences is divided into multiple subtypes namely A, B, C, D, F, G, H, J, K and 
circulating recombinants (8). Subtypes B and C account for most of the group M infected 
individuals with specific geographic distribution (9). Subtype B HIV-1 is predominant in Northern 
America and Western Europe (9), while subtype C infections account for half of all HIV-1 
infections globally (10) and is predominant in India and Sub-Saharan Africa (9), where its 
prevalence is high (as high as 25% in South Africa, ref) (11) (ref).  
Transmission of HIV-1 can occur by mucosal, perinatal and parenteral routes (7) and of 
these, mucosal transmission accounts for approximately 90% of all new infections worldwide (12) 
(7) (2). Heterosexual (HSX) exposure is the predominant route of transmission and is responsible 
for nearly 70% of all infections worldwide (7), with men who have sex with men (MSM) accounting 
for approximately 20% (2). Sexual transmission of HIV-1 is a relatively inefficient process and 
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studies estimate the probability of transmission per sexual exposure to range from 1 in 20 to 1 in 
3000 (12-18) depending on the route of exposure. However, factors like increased donor viral 
load, concomitant sexually transmitted diseases (STD) with resultant inflammation and ulcers, 
altered mucosal microbiota, socioeconomic factors and gender of the recipient can influence 
transmission efficiency (17-36). HIV-1 infection causes the depletion of CD4+ T cells, a subset of 
T cells essential for the proper functioning of the immune system(37) (37-39), Decline in CD4+ 
counts below 200 cells/ul is AIDS-defining (40), results in immunodeficiency, opportunistic 
infections and ultimately death (41-44). Despite the advent of highly active antiretroviral therapy 
(HAART) and other promising intervention strategies (45), a broadly effective vaccine remains the 
most cost effective means to stem this public health problem (46, 47) (48).  
 
 
HIV-1 Entry and Early Events 
Infection by HIV-1 involves the interaction of the viral envelope glycoprotein (Env) with its 
receptor (CD4), a conformational change in Env facilitates binding to coreceptor and entry into 
susceptible target cells (49). C-C chemokine receptor type 5 (CCR5) and C-X-C chemokine 
receptor type 4 (CXCR4) are the primary coreceptors used by HIV-1, of these CXCR4 usage is 
limited and typically occurs in the chronic stage of infection in certain individuals (50) (51), while 
acute viruses predominantly use CCR5 (52-54). For obvious reasons, studying the early events in 
HIV-1 transmission in humans is impractical, and thus much of what is known about transmission 
comes from observations of experimental infections in the simian model of HIV-1 infection 
(SIVmac infection of rhesus macaques) (55). In the next few paragraphs, results from the studies 
of HIV-1 and SIV will be used to describe the early events following exposure. In the SIV model, 
both cell-free (56) and cell associated (57) virus stocks are capable of initiating infection (58), 
using both high challenge doses and  a low-dose escalation strategy. Multiple sites in the female 
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genital tract including the ectocervix, transitional zone, endocervix and the vaginal epithelium 
have been demonstrated to be potential sites of infection(59-61) (62-65) (66). Similarly, foreskin, 
penile tissue and rectum are sites of infection in males (61, 67-71).   
While SIV RNA + cells are observed as early as 2 hours following exposure (62), the 
identity of these initial target cells is still a controversial subject. The main cell type that sustains 
viral replication is activated CD4+ T-cells. However, studies of SIV suggest that myeloid cells 
could be initially infected and transmit virus to underlying CD4+ cells (58, 66, 72-74). 
Alternatively, Haase and colleagues describe a model where resting CD4+ cells are the first cells 
to become infected (62, 65, 75, 76), although these cells are hard to infect in-vitro (77, 78). In a 
third model, predominantly described by Steinman and colleagues describe how dendritic cells 
(DCs) interact with HIV-1 and transfer infectious viral particles to CD4+ T-cells, without 
themselves getting infected (79-81).  
 
Following transmission, a series of viral and host immune markers appear that are 
reproducible across individuals irrespective of virus subtype or route of transmission. This set of 
markers was first described by Fiebig and colleagues and is helpful to stage individuals during 
acute infection (82).  
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Figure 1.1. Stages of infection and the immunopathogenesis of HIV-1 infection. The phases of 
HIV-1 infection can be divided into six, distinct stages (82) based on the appearance of viral RNA, 
the gag antigen, antibodies for HIV-1 proteins, first detectable by ELISA and then by western blot, 
and these are indicated above the viral load curve. The lines beneath the viral load curve indicate 
early events and immune responses in the host, beginning with the establishment of viral latency, 
and the development of CD8 T-cell responses and binding and neutralizing antibodies. Figure 
from (32) 
 
There is an initial eclipse phase before the first detection of virus in the blood, followed by 
the appearance of viral RNA (Fiebig I), viral p24 antigen (Fiebig II), virus specific antibodies 
detected first by ELISA (Fiebig III) and then by western blot (Fiebig IV-VI) (Fig 1.1) (82). Shortly 
after the eclipse phase, there is an exponential increase in viral RNA levels as the virus spreads 
from local expansion in submucosal CD4+ T cells to secondary lymphoid tissue like the gut 
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associated lymphoid tissue (GALT) (7). This exponential viral replication is characterized by a 
high reproductive ratio (R0) of 8 (83).  R0 is a measure of the number of cells that become infected 
by virions produced by a single infected cell. Viruses with an R0 > 1 will result in a spreading 
infection, while viruses with an R0 < 1 will be extinguished (84).  
 
Bottlenecks during mucosal transmission 
Individuals with chronic HIV-1 infections harbor viral populations with extensive genetic 
diversity (85). These intra-patient virus populations are commonly referred to as ‘quasispecies’ 
because they consist of non-identical, yet related viral genomes subjected to constant variation, 
competition and selection pressure (86).  In strong contrast, viral populations in most newly 
infected recipients are far more homogenous (7, 87-92). The narrowing in genetic diversity 
observed during transmission is termed the transmission bottleneck (7, 90). Single genome 
sequencing (SGS) allowed the determination of the extent of the transmission bottleneck, and the 
unambiguous inference of the viral genome that initiated infection, termed the transmitted founder 
(TF) virus (52, 93, 94). This method eliminates Taq polymerase induced errors, template 
switching and non-proportional representation of viral variants, all problems observed with bulk 
PCR followed by cloning and sequencing (95-103) (93). During early acute infection, viral 
evolution occurs in the absence of the adaptive immune response and thus during the earliest 
phases of infection, viral diversification occurs in a random manner (32, 52, 82). 
The stringency of the transmission bottleneck depends to a certain degree on the route of 
transmission (30, 52, 104-107) (Fig 2). Using SGS, multiple studies have shown that 80% of all 
mucosal infections are initiated by a single viral variant (7) (Table 1.1) with HSX transmission 
(81% single variant) associated with a more stringent bottleneck than that observed with MSM 
(62% single variant) (Fig 2).  However, even in HIV-1 transmission by injection drug users (IDU), 
half of all new infections are associated with the transmission of a single variant (106, 107). 
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Taken together, these results indicate that there are likely hurdles to viral infection beyond the 
mucosal surface.   
 
 
Table 1.1 Stringency of HIV-1 transmission by different routes. Transmission by heterosexual 
(HSX) contact is the most stringest, with 80% of new infections initiated by a single transmitted 
variant. This is irrespective of the gender of the donor and recipient. Transmission among men 
who have sex with men (MSM) is less stringent, with close to 40% of new infections being 
Risk 
group Study Subjects 
Single  
variant Multiple variants Median Range 
 
HSX 
 
Keele 79 65  82% 14  18% 1 1-4 
Abrahams 69 54  78% 15  22% 1 1-5 
Haaland 27 22  82% 5  19% 1 1-6 
  Total 175 141  81% 34 19% 1 1-6 
MSM Keele 22 13  59% 9  41% 1 1-6 
Li 28 18  64% 10  36% 1 1-10 
  Total 50 31  62% 19  38% 1 1-10 
IDU Bar  10 4  40% 6  60% 3 1-16 
Masharsky 13 9 69% 4 31% 1 1-3 
Total 23 13 56% 10 44% 1 1-16 
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initiated by multiple variants, likely associated with the breach in mucosal barrier function. 
Transmission among injection drug users (IDU) is the least stringent with 45% of infections 
initiated by multiple variants, consistent with the absence of a protective mucosal surface. Data 
compiled from (30, 52, 104-107) 
 
 
What are the reasons for the observed transmission bottleneck? The transmission 
bottleneck is a result of selective processes that impact various stages of the transmission 
process (108). (fig 1.2)  
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Fig 1.2 Multiple genetic bottlenecks that can influence the Transmitted founder virus, Chronically 
infected individuals harbor extensive genetic diversity. Viruses from the blood seed the genital 
tract of the donor, potentially resulting in clonally amplified lineages which become genital tract-
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specific. A minor variant from this population is selected for during transmission, resulting in a 
genetically homogenous founder population derived typically from a single viral variant. Evolution 
of the virus In the host, especially in response to the adaptive immune response results in the 
diverse, chronic quasispecies. Figure from (108) 
 
 
Mucosal tissues can form physical barriers to transmission, and likely contribute to the low 
efficiency of HIV-1 transmission. In the female genital tract (FGT), the vagina and ectocervix are 
lined by multilayered squamous epithelium (61). This thick layer of tightly-packed cells prevents 
the contact of virus with underlying target cells. In contrast, the transition zone between the ecto 
and endo – cervix is lined by a single layer of epithelial cells and has an abundance of CD4+ 
target cells, and thus constitutes a site with increased susceptibility (109, 110). In contrast, the 
exposed part of the male genital tract (MGT) is lined by keratinized, stratified squamous epithlium 
and is likely more restrictive for transmission (7, 61, 111). The fact that male circumcision 
decreases the risk of transmission indicates that the penile foreskin is an important route for 
transmission (61, 68, 69, 112). In addition, mucosal cells can release microbial defensins that 
inhibit transmission (113, 114) and mucus that lines these surfaces – cervicovaginal mucus 
(CVM) or rectal mucus can retard viral diffusion (115-117). The importance of this first line of 
defense is underscored by the observation that ulcerative infections and microabrasions during 
sexual contact can mitigate mucosal barrier function(7, 30). The differences in the mucosal 
barriers that transmitted viruses overcome depending on the route of transmission can likely 
influence the phenotypes of these viruses. (31, 108, 118, 119).  
In addition to these physical barriers, viral compartmentalization in different tissues of the 
body (blood, genital tract, lymph nodes) and the selection of specific variants to seed the genital 
tract can contribute to the observed transmission bottleneck (Fig 3). Evidence for genital tract-
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specific viruses has been reported (87, 120-127). Interestingly, Boeras and colleagues have 
demonstrated that the TF is not drawn from the major genital tract viral variant and is in fact a 
minority variant, more related to viruses in the blood (121). Additionally, viruses that are sensitive 
to neutralizing antibodies present in either the semen or cervicovaginal fluid might be prevented 
from transmission (108).  
Concomittant infections of the genital tract can contribute to higher rates of HIV-1 
acquisition and increased frequency of multiple variant transmission by enhancing inflammation 
and immune activation, and providing increased activated target cells (30, 128-131). Beyond the 
mucosa, viral particles must locate and enter subepithelial CD4+ T-cells, undergo replication and 
dissemination to secondary lymphoid tissue(55). Overcoming the innate immune system is an 
important early step in the establishment of infection. Miller and colleagues have shown the 
induction of type I IFN in tissue regions which are SIV+ (132) and recent unpublished data from 
Jake Estes suggests the induction of type I IFN can extinguish early foci of viral replication. Thus 
the selective forces that act at transmission are multiple and might limit seroconversion and the 
numbers of transmitted variants(108).  
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Section 1.2 The host immune response to HIV-1 infection  
 
Exposure to virus, initiates a signaling cascade  that involves the production of cytokines 
like CCL20, MIP1a and others by epithelial cells resulting in the recruitment of plasmacytoid 
dendritic cells (pDCs)  and activated CD4+ T cells generating fresh target cells to fuel the new 
infection (55, 58, 61, 65, 133, 134). Borrow and colleagues measured the levels of 30 plasma 
cytokines and chemokines in sequential plasma samples from acutely infected blood donors 
during the eclipse and early exponential phase of infection (135). This study found that the acute 
phase of HIV-1 replication is characterized by a ‘cytokine storm’ with some cytokines like 
Interferon alpha (IFN-α) and interleukin 15 (IL-15) being produced early and transiently while 
others demonstrate larger (Interferon gama induced protein 10, IP-10) or more sustained 
increases (tumour necrosis factor alpha, TNFa and monocyte chemoattractant protein 1, MCP-1). 
Dendritic cells, both myeloid (mDC) and plasmacytoid (pDC) are responsible for the slower, 
sustained cytokines and rapid, transient cytokines respectively. This cytokine cascade can 
contribute to the control of viral infection including the activation of effector mechanisms like 
natural killer (NK) cells and priming of the adaptive immune response (136-138). Conversely, the 
production of immunostimulatory cytokines can enhance early viral replication through the 
provision of susceptible, target cells (132, 139).  
 
 
The innate immune response to HIV-1: Type I Interferons 
HIV-1 Env-CD4 interactions result in the endocytosis of viral particles into pDCs. Viral 
nucleic acids, particularly RNA in the endosome stimulate toll-like receptor 7 (TLR7), which 
activates pDCs, inducing the secretion of type I Interferon (IFN) (140, 141) via myeloid 
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differentiation primary response gene 88 (MYD88) and interferon regulatory factor 7 (IRF7). 
Alternatively, in other CD4+ cells HIV-1 cDNA is sensed following infection. In these cells, reverse 
transcription products are sensed by cytoplasmic sensors like cyclic GMP-AMP (cGAMP) 
synthase (cGAS) and IFNg – inducible protein 16 (IFI16) (141-144). These sensors signal 
through stimulator of IFN genes (STING) and IRF3. Both of these signaling pathways converge 
on the production of IFN (shown in Fig 1.3). Compared to all the cell types present in the blood, 
pDCs produce 200-1000 times more IFN after microbial microbial exposure (145).
 
Fig 1.3 Intracellular sensing of HIV-1 infection in an infected host. Following binding and 
entry into a cell, reverse transcription products are sensed by cGAS and IFI16 which activate a 
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signaling cascade ultimately resulting in the induction of type I interferons. In addition to cDNA, 
viral RNA can also be sensed by TLR7 in the endosomes of pDCs. Figure from (141) 
 
There are three families of IFN (type I, II and III) of which, type I IFNs are primarily 
responsible for antiviral effects against HIV-1 (141, 146, 147). Type I IFNs consist of 12 alpha 
subtypes, IFN-β, IFNw, IFNe and IFNk (148, 149). These IFNs act in both an autocrine and 
paracrine fashion to signal through the heterodimeric interferon receptor (IFNAR) (150). This 
receptor is made up of two subunits (IFNAR1 and IFNAR2) and ligation of the receptor causes 
downstream signal transduction through the Janus kinase (JAK) and signal transducer and 
activator of transcription (STAT) pathways (151) (ref). STAT1/2 dimers can bind to IRF9, which in 
turn binds to the IFN-stimulated response elements (ISREs) in the promoters of IFN stimulated 
genes (ISGs) (ref). There are over 300 ISGs with anti-viral, anti-tumour, anti-proliferative and 
immunoregulatory activities (152).  
Type I IFNs bind and signal through IFNAR, yet different subtypes are reported to have 
distinct biological functions (153, 154). The IFN subtypes differ in their affinity for receptor 
subunits (152, 154-156), and this coupled with differences in off-rates are thought to be 
responsible for the variety of downstream effects (152). Consistent with this, different subtypes of 
IFN-α inhibit HIV-1 replication to different levels. A recent study (157) found that IFN a8, a14 and 
a6 potently reduced the number of infected cells and the production of infectious viral particles 
while subtypes a21, a1 and a2 had more modest effects. This is relevant and extremely critical to 
verify, as IFN-α2 is most commonly used in clinical trials (158-169). Veazey and colleagues 
demonstrated that the topical application of human IFN beta to vaginal tissue of rhesus 
macaques prevented the animals from simian human immunodeficiency virus (SHIV) acquisition 
(170). This protection was observed despite an increase in immune activation. In this study, the 
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authors mention that IFN b was the most potent at suppressing HIV-1 replication when compared 
to other alpha subtypes.  
While clearly antiviral, recent studies addressing the roles of IFN during acute and 
chronic infection revealed complex and antagontistic effects. Sandler and colleagues found that 
the administration of IFN-α2 to rhesus macaques prior to challenge was protective, and 
associated with the increase in antiviral gene expression, while treatment with an IFN receptor 
antagonist resulted in accelerated progression to AIDS. Paradoxically, prolonged administration 
of IFN caused reduced response to IFN, reduced antiviral gene expression and more rapid loss of 
CD4+ T-cells (171). These findings are consistent with previous studies that found persistently 
elevated levels of IFN and ISGs are associated with increased viral loads (172, 173).  
The levels of endogenous IFN fluctuate over the course of HIV-1 infection. After the rapid 
and transient elevation observed in acute infection, levels of IFN are thought to return to baseline, 
and are undetectable in the plasma of infected individuals (135). However, during chronic 
infection and particularly during progression to AIDS, IFN-α2 levels increase (174, 175), 
accompanied by an increase in viral load and CD4+ T-cell decline. Taken together, these results 
underscore the complex, fine balance between the protective, beneficial and antiviral effects of 
type I IFNs and the detrimental and inflammatory effects, especially observed with prolonged 
exposure. However, in acute infection, elevations in type I IFNs are clearly protective and 
associated with restricting transmission (171, 176, 177).   
 
The adaptive immune response to HIV-1 infection 
The cellular adaptive immune response to HIV-1 is well characterized and associated 
with a decline in peak viremia after acute infection (178). In fact, the speed of activation of HIV-
specific CD8+ T-cells, visible in the first ten days after detectable viremia, and the magnitude of 
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this response govern subsequent immune control and acute phase resolution (179). This 
cytotoxic T-lymphocyte (CTL) response places selective pressure on the virus and is evidenced 
as viral evolution in sites of CTL pressure, outgrowth of viral escape mutants and the replacement 
of the wildtype infecting strain (180, 181). Importantly, the depletion of CD8+ T cells in the simian 
model of AIDS demonstrated the role that these cells play in early viral control and decline from 
peak viremia (182).  
The humoral response to HIV-1 arises early in infection, resulting in the production of 
binding antibodies (Ab) with no discernible effect on viremia and that do not exert selective 
pressure on the acute virus (183). Neutralizing antibodies (Nab) are those that bind viral particles 
and prevent them from infecting target cells. These Nabs appear later in infection and are limited 
in their breadth of neutralization, that is, they can neutralize the virus in the individual in which 
they arose but cannot neutralize a virus from a different individual. These Nabs are potent 
enough however, to drive virus escape as evidenced by the selection of escape mutations (183, 
184).  
Adaptive immune responses drive viral evolution and can thus impact disease 
progression. Shortly after transmission, HIV-1 establishes a reservoir of latently infected cells 
(185, 186). These latently-infected cells harbor integrated proviruses, are generally not 
permissive for viral gene expression, are extremely long-lived and present the major hurdle to 
curing HIV-1 infection(185). Given this, the virus might be most vulnerable early in infection 
between the eclipse phase and peak viremia. This leaves a small window of opportunity for 
interventions (187) and hence it is of interest to determine the properties of the transmitted virus 
because interventions and vaccines aimed at blocking transmission would need to target any 
specific features of the transmitted virus.  
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Section 1.3 Transmitted Variants: Genetic and Biological traits 
Single genome amplification followed by direct amplicon sequencing (SGS) made 
possible the inference and enumeration of transmitted variants (52, 93). The unambiguous 
description of the viral genome that initiated and founded clinical infection, allowed the 
comparison of genetic features of TF and non-transmitted variants. As Env is the first viral protein 
to interact with host cells, many early studies focused on this protein (118, 188-193). A functional 
Env is a trimer of heterodimers. Each heterodimer is made up of a surface unit (gp120) and a 
transmembrane portion (gp41). Surface unit gp120 is made up of both constant regions and 
variable loops, and is a heavily glycosylated protein (49). Env sequences from individuals with 
acute subtype C infections have been reported to have fewer potential N-linked glycosylation 
sites (PNLGs) and shorter variable loops when compared to Env sequences from respective 
donors or unmatched random chronically infected individuals (118, 190). However, many of the 
findings are not reproducible across cohorts or viral subtypes. Indeed, in studies of subtype B 
viruses, researchers have often found no differences in either the length of the variable loops or 
PNLGs (188, 192, 194, 195) or found differences in only the PNLGs (196). In studies of subtype 
A and D viruses, recipient viruses have been reported to have shorter variable loops (191, 192), 
but either the same (191) or fewer PNLGs (192). Comparisons of Env sequences from acutely 
infected individuals to all sequences in the Los Alamos National Laboratory HIV sequence 
database yielded shorter variable loops and fewer PNLGs for subtype A but not subtype B (192). 
Thus, while these Env genotypic features appear to be selected in certain cohorts and subtypes, 
they are not easily generalizable. Additionally, some of these differences can be attributed to 
differences in the populations and cohorts studied.  
TF viruses have been shown to be more closely related to minor variants in the donor 
quasispecies (121). A large signature analysis study of subtype B Env sequences identified 
transmitted signatures in the signal peptide and in gp120, the latter involved the loss of a glycan 
which has been shown to be associated with immune escape (197).  A recent study comparing 
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sequences from 137 transmission pair donors and recipients and found that recipient sequences 
were closer to the subtype consensus sequence than the matched donor sequences (31). The 
transmission of more ‘ancestral’ forms has been described previously (198-201)  and is 
interpreted to indicate the transmission of more ‘fit’ viruses. In fact, in chronically infected 
individuals, viruses with immune escape mutations often infer a fitness cost (181, 184, 202-207). 
Upon transmission to a naïve recipient, these mutations often revert to consensus amino acid 
residues (208). The suggestion that more ancestral genomes were indicative of higher fitness 
merited an investigation into the biological properties of TF viruses. 
The most widely observed, robust finding is that transmitted variants use CCR5 as a 
coreceptor for entry (52, 53, 118, 188, 189, 193). Multiple studies have interrogated the efficiency 
of receptor and coreceptor usage, hypothesizing that efficient viral replication might require 
enhanced receptor binding. However, no differences between TF and chronic Envs have been 
reported in the efficiency and speed of fusion of viral Envs with CD4 (188, 189), and TF viruses 
have been reported to require high levels of CD4 to mediate entry (118). Additionally, subtype B 
and C TF Envs were indistinguishable from chronic Envs in their entry into different primary CD4+ 
T-cell subsets (188, 189). While some reports have identified the integrin a4b7 as a molecule 
preferentially bound by TF Envs (209)(Arthos), a subsequent study looked at a larger panel of 
Envs and failed to see these differences (189). We and others have observed that TF Envs are 
more sensitive to inhibition by maraviroc, a drug that blocks Env- CCR5 interactions, and this is 
observed for both subtypes B and C (118, 193).  
These previous studies have focused on Env in isolation, and to more thoroughly study 
TF biology, the interrogation of other viral proteins is important. A comprehensive study of full-
length replication competent viruses from subtypes B and C found TF viruses have more Env per 
particle, were more infectious, interacted more efficiently with DC, were transferred more 
efficiently from DC to CD4+ T-cells and were more resistant to IFN-α (54). The caveat to this 
study was that the acute and chronic viruses were derived from unmatched individuals. In 
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agreement with the results from Parrish and colleages, Fenton-May et al., found that transmitted 
viruses were resistant to IFN-α, and that this resistance declined six months after transmission 
(210). In this study, the authors compared the IFN-α resistance of the TF from an infected subject 
to the consensus virus six months later. To determine if these properties were observed in 
viruses from linked donors and recipients, subsequent studies used known transmission pairs 
(195, 201). Surprisingly, these studies did not reproduce Parrish and colleagues’ findings. They 
found that recipient viruses were equally infectious and have similar replicative capacity (195, 
201). Deymier et al found that recipient viruses were equally resistant to IFN-α, while Oberle and 
colleagues found recipient viruses to be slightly more sensitive to IFN-α. Limited sampling of the 
donor and the source of the donor viruses were caveats in these studies that might have resulted 
in their findings. Thus, while there are hints that transmitted viruses are distinguished by genetic 
and biological properties, a more thorough investigation, with larger panels of viruses are 
warranted.   
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Section 1.4 HIV-1: accessory proteins and ISG counteraction 
HIV-1 has a positive sense RNA genome that encodes three structural proteins –group-
specific antigen (gag), polymerase (pol) an envelope (env)  and 2 regulatory proteins – 
transactivator of transcription (tat) and regulator of expression of virion proteins (rev) (211). In 
addition, the virus encodes four accessory proteins, so named because they were believed to be 
dispensible for replication in-vitro (212). They are virion infectivity factor (vif), viral protein r (vpr), 
viral protein u (vpu) and negative factor (nef). Their organization is shown in Fig 1.4  
 
 
 
Fig 1.4 Genomic organization of the coding and non-coding regions of HIV-1. Viral polyproteins 
and their constituent proteins are indicated. In addition, exons and splice junctions of accessory 
proteins are indicated. The genes are organized by reading frame and aligned to HXB2 as a 
reference. Figure from http://www.hiv.lanl.gov/ 
 
 
The four accessory proteins are involved in escape from and manipulation of innate and 
adaptive immune responses (213). None of these proteins have enzymatic activity; instead they 
act as molecular adaptors linking their targets to the host degradation pathway (214). Multiple 
host proteins termed restriction factors act in concert to restrict various stages of the viral life 
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cycle. These factors are distinguished by being inducible by type I IFNs, encoded by the 
germline, under positive Darwinian selection and they are frequently counteracted by viral 
proteins (141). These factors act to restrict virus replication and transmission between individuals 
of the same species but also can act as barriers to cross-species transmission events (3, 215-
217). 
 
A role for Vif was identified by researchers who observed a reduction in viral infectivity of 
Vif deficient viruses in primary CD4+ T-cells and certain cell lines (218-221). Sheehy and 
colleagues identified apolipoprotein B mRNA-editing enzyme, catalytic polypeptide like 3G 
(APOBEC3G) as the host protein that is packaged into viral particles and deaminates nascent 
reverse trancripts (222). This deamination results in the insertion of alanines in place of guanines 
during second strand cDNA synthesis, and is referred to as G-A hypermutation. A3G is a member 
of the A3 family of type I IFN-inducible, cytidine deaminase proteins, and A3 D, E, F, G and H are 
reported to have anti-HIV activity (223). A3G deamination results in hypermutated viral DNA, 
which can either be destroyed prior to integration or might integrate, largely encoding defective 
viruses. Binding of A3G to nascent trancsripts can also inhibit reverse transcription and block the 
process of integration (223). In the presence of Vif, members of the CUL5-EloB/ C-RBX2-E2 
complex are recruited to A3, resulting in their polyubiquitination and proteosomal degradation. 
Thus, A3G is excluded from the viral particle and cannot influence infectivity in the subsequent 
round of infection(223).  
 
Vpu was first shown to be important for the efficient release of viral particles from certain 
cell types (224-227). Based on the requirement for Vpu, cells could be classified as permissive 
and non-permissive. In the absence of vpu, in non-permissive cells, virions stay associated with 
the infected cell surface (226), held there by a proteinaceous tether (228, 229), and are thus not 
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released efficiently (226, 230). The responsible host protein, tetherin/ CD317/ BST2 (229, 231) is 
IFN-α inducible (228, 229) and retains viral particles which can then  be endoctyosed (228, 230).  
Tetherin is a transmembrane protein with a C-terminal glycosylphophatidylinositol (GPI) anchor. It 
is expressed on cells as a short and long isoform due to the presence of an internal initiation 
codon (232), both of which are restrictive, but only the long form retains Vpu sensitivity. Vpu 
directs the ubiquitination and lysosomal degradation of tetherin via linking it to the adaptor b-
TRCP(233).  While tetherin can inhibit virus release, its role in the restriction of virus replication is 
contentious. Some groups have reported the ability of cell-cell spread of HIV-1 to overcome 
restriction by tetherin (234), while others have demonstrated that tetherin can restrict both cell-
free and cell-cell spread of HIV-1(235). Thus, it appears that tetherin at least plays an important 
role in limiting cell-free virus production, which could influence transmission.   
 
Vpu is not the only lentiviral protein capable of antagonizing tetherin. Certain SIVs and 
HIV-2 use Nef and Env respectively to counteract tetherin, underscoring the importance of the 
counteraction of this restriction factor (214). SIVcpz and SIV gor viruses utilize their Nef protein to 
counteract tetherin. Human tetherin has a 5 amino acid deletion in the N-terminal cytoplasmic 
region. This deletion renders human tetherin resistant to antagonism by Nef, whose binding site 
overlaps with this region (215, 236). Upon cross-species transmission of SIVcpz to humans, HIV-
1 M adapted to use Vpu to counteract this host protein, switching from interacting with the 
cytoplasmic domain using Nef to the transmembrane domain using Vpu (215). Indeed this 
adaptation is believed to be critical for HIV-1’s effective spread in the human population (3). 
Among the groups of HIV-1, M and N use Vpu to antagonize tetherin, although the latter is very 
inefficient (215, 237). Previous reports indicate that groups O and P Vpu proteins do not 
counteract tetherin (215, 236, 238-240).  
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In addition to the counteraction of tetherin, Vpu also downmodulates CD4 and NFkB. The 
downregulation of CD4 prevents viral superinfection of an infected cell and prevents the 
interaction of CD4 and Env intracellularly, thus freeing newly synthesized Env for incorporation 
into particles and viral release (241-244). NFkB can induce antiviral gene expression, and thus 
especially in late stages of viral replication, its expression can be disadvantageous. Vpu proteins 
of different SIVs and HIV-1 downregulate NFkB, thus preventing sensing of the virus, and 
downstream antiviral effector expression (245, 246). Thus, in addition to the counteraction of 
ISGs, accessory proteins also interfere with viral sensing to avoid the induction of type I IFNs. 
 
Vpr has been reported to induce cell cycle arrest at the G2/M transition (247-249). More 
recently, Vpr has been demonstrated to interact with the SLX4 scaffold protein and structure-
specific endonucleases. The formation of this complex (SLX4com) results in its activation and 
thus G2/M cell cycle arrest. The activation of SLX4com is beneficial to HIV-1 replication through 
the impairment of the host cell’s ability to sense infection and induce type I IFN production (250, 
251). Following activation of the complex, endonucleases degrade viral transcripts enabling the 
virus to escape detection by the host innate immune mechanism (250).  
 
Nef is an early viral protein, whose expression while dispensable in vitro, is crucial for the 
maintenance of high viral loads in HIV-1 infected humans and SIV infected macaques in vivo 
(252, 253) (254). Nef, similar to Vpu, downregulates CD4 from the cell surface (255), and in doing 
so prevents cell death by the possible recognition of Env-CD4 complexes by antibody-dependent 
cell-mediated cytotoxicity (ADCC) (256, 257).  While Vpu targets newly synthesized CD4 in the 
endoplasmic reticulum (ER), Nef, by virtue of being an early protein, targets CD4 expressed on 
the cell surface. Nef recruits adaptor protein 2 (AP-2) and induces the clathrin-dependent 
endocytosis of CD4 and ultimately its degradation (258). In addition to CD4, Nef also 
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downmodulates major histocompatibility complex 1 (MCH I) from the cell surface. This reduces 
the presentation of viral antigens to CD8+ T cells and thus prevents infected cell death (ref). Nef 
also regulates NFkB expression (259). NFkB has a dual role during viral infection, early in 
infection it binds to the long terminal repeat (LTR) in the integrated provirus and stimulates 
transcription (ref), while late in the life cycle its expression can enhance viral sensing. Nef, 
induces the levels of NFkB early in the viral life cycle, thereby inducing transcription and viral 
replication (260).  
 
Nef has additionally been shown to be crucial to promote viral infectivity (ref). It was thus 
hypothesized that Nef altered the cell surface expression and potential incorporation of a cellular 
factor that limited virion infectivity (261). Two groups recently identified this protein as Serine 
incorporator (SERINC) 3 and 5 (262, 263). SERINC proteins do not inhibit Env fusion with the 
target cell, instead they block infection at the expansion of the fusion pore(264). However, 
SERINC is not IFN-α inducible, and is thus not considered a restriction factor, but a cell intrinsic 
viral factor. Lastly, as mentioned above many SIVs use their Nef proteins to counteract tetherin. 
While groups M and N use their Vpu protein to antagonize this host protein, groups O and P do 
not, and in fact previous studies suggest that neither has evolved an efficient protein capable of 
counteracting tetherin(215, 238, 239). While consistent with the limited spread of group P viruses 
in the population, it is puzzling how group O viruses have infected nearly 100,000 people in the 
absence of an efficient tetherin antagonist.  
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Conclusions 
In sum, mucosal transmission of HIV-1 is characterized by a stringent bottleneck. While 
genetic and phenotypic signatures of transmission have been described for Env proteins, these 
have not been extended to other viral proteins. Determining the biological phenotypes of full-
length, mucosally transmitted HIV-1 will enable a more precise understanding of the processes 
that limit transmission. I hypothesize that transmitted viruses are characterized by unique 
biological properties that distinguish them from non-transmitted donor viruses. In addition, these 
properties will enable the successful transmission across mucosal surfaces, and enable efficient 
viral replication in a newly infected recipient. In Chapter 2, I investigate the properties of 
transmitted viruses by comparing them to non-transmitted variants in the context of established 
transmission pairs. Evaluating the role of restriction factors and their contribution to the mucosal 
bottleneck could reveal interesting and novel therapeutic angles. Specifically, in chapter 3, I 
address the contribution of tetherin to the antiviral state established by IFN-α. Complimentary to 
this, I determine the importance of Vpu in overcoming IFN-mediated HIV-1 restriction.   
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CHAPTER 2 
 
 
 
RESISTANCE TO TYPE 1 INTERFERONS IS A MAJOR DETERMINANT OF HIV-1 
TRANSMISSION FITNESS 
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Section 2.1 – Abstract 
 
 
 
Sexual transmission of HIV-1 is an inefficient process, with only one or few variants of the donor 
quasispecies establishing the new infection. A critical, and as yet unresolved, question is whether 
the mucosal bottleneck selects for viruses with increased transmission fitness. Here, we 
characterized 300 limiting dilution-derived virus isolates from the plasma, and in some instances 
genital secretions, of eight HIV-1 donor and recipient pairs. Although there were no differences in 
the amount of virion-associated envelope glycoprotein, recipient isolates were on average 3-fold 
more infectious (P = 0.0001), replicated to 1.4-fold higher titers (P = 0.004), were released from 
infected cells 4.2-fold more efficiently (P < 0.00001), and were significantly more resistant to type 
I interferons (IFNs) than the corresponding donor isolates. Remarkably, transmitted viruses 
exhibited 7.8-fold higher IFNα2 (P < 0.00001) and 39-fold higher IFNβ (P < 0.00001) half-maximal 
inhibitory concentrations (IC50) than did donor isolates, and their odds of replicating in CD4+ T 
cells at the highest IFNα2 and IFNβ doses were 35-fold (P < 0.00001) and 250-fold (P < 0.00001) 
greater, respectively. Interestingly, pretreatment of CD4+ T cells with IFNβ, but not IFNα2, 
selected donor plasma isolates that exhibited a transmitted virus-like phenotype, and such 
viruses were also detected in the donor genital tract. These data indicate that transmitted viruses 
are phenotypically distinct, and that increased IFN resistance represents their most distinguishing 
property. Thus, the mucosal bottleneck selects for viruses that are able to replicate and spread 
efficiently in the face of a potent innate immune response.  
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Section 2.2 – Significance 
 
Effective prevention strategies are urgently needed to control the spread of HIV-1. A critical 
barrier to developing such strategies is the lack of understanding of the host antiviral defenses 
that control HIV-1 replication in the mucosa at the site of entry. Here, we characterized viruses 
from matched donor and recipient pairs to determine whether transmitted HIV-1 strains exhibit 
traits that increase their transmission fitness. Characterizing 300 limiting dilution-derived isolates, 
we identified several properties that enhance virus replication in the face of a vigorous innate 
immune response, of which resistance to type 1 IFNs is the most important. These results provide 
new insights into the HIV-1 transmission process and define possible new targets for AIDS 
prevention and therapy.  
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Section 2.3 – Introduction  
 
Understanding the host and viral factors that influence HIV-1 transmission may aid the 
development of an effective AIDS vaccine. In 2015, approximately 2 million individuals were 
newly infected with HIV-1, the great majority of whom acquired the virus by sexual routes (1). 
Although a number of factors, such as high donor viral loads, genital inflammation, altered 
mucosal microbiota, and recipient gender, are known to increase the infection risk (2-4), virus 
transmission across intact mucosal surfaces is inherently inefficient, with only a small fraction 
(less than 1%) of unprotected sexual exposures leading to productive infection (5-8). This 
inefficiency is exemplified by a stringent population bottleneck, in which only one or a limited 
number of variants from the diverse quasispecies of the transmitting donor establish the new 
infection (9). Transmitted viruses are not usually the most abundant strains in the genital 
secretions of infected donors (10), and analyses of viral sequences from 137 matched donor and 
recipient pairs indicated that viruses with a more ancestral genotype are preferentially transmitted 
(11). These data suggested that mucosal transmission selects for variants with enhanced 
transmission fitness (11). However, the viral properties that contribute to this transmission fitness 
have not been defined.  
 For obvious reasons, viruses cannot be collected from, or studied in, humans at the time 
of transmission. However, by sequencing plasma virion RNA (vRNA) in the first few weeks 
following transmission, it is possible to enumerate and infer the genome(s) of the virus(es) that 
established the infection (9, 12-14).  In the absence of adaptive immune pressures, HIV-1 
diversifies in a random fashion, with viral sequences exhibiting a Poisson distribution of mutations 
and a star-like phylogeny that coalesces to an inferred consensus sequence. This consensus 
sequence represents the genome of the virus that initiated the infection, termed the transmitted 
founder (TF) virus (9). Single genome amplification (SGA) of plasma vRNA, which precludes PCR 
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artifacts such as Taq polymerase mediated recombination (15-18), revealed that in the great 
majority (~80%) of sexual transmission cases, a single TF virus establishes the new infection (9, 
12, 13, 19-21). 
 The ability to infer and molecularly clone the genomes of TF viruses has permitted their 
biological characterization. Initial studies showed that TF viruses use CD4 and CCR5 as their 
receptor and co-receptor, and replicate efficiently in activated CD4+ T cells but not macrophages 
(14, 22-25). Moreover, analysis of a comprehensive panel of infectious molecular clones (IMCs) 
showed that TF viruses packaged more envelope glycoprotein (Env), exhibited greater infectivity, 
bound to monocyte-derived dendritic cells more efficiently, and replicated to higher titers in CD4+ 
T cells in the presence of the type 1 interferon IFNα2 than chronic control (CC) viruses (26). 
However, a potential confounder of these studies was the fact that TF and CC viruses were not 
derived from epidemiologically linked transmission pairs. To compare transmitted and non-
transmitted viruses close to the time of transmission, two recent studies characterized the 
phenotype of viruses from matched donor and recipient pairs (27, 28). Examining various 
biological properties, including the sensitivity of donor and recipient viruses to IFNα2, both studies 
failed to identify viral traits that were indicative of enhanced transmission fitness (27, 28). 
 Innate immune responses, in particular type 1 IFNs, represent a potent first-line defense 
against many pathogens, including primate lentiviruses (29-33). Consistent with this, treatment of 
rhesus macaques with pegylated IFNα2 increased the number of intrarectal challenges required 
to achieve systemic SIVmac infection and decreased the number of transmitted founder viruses 
(34). Similarly, mucosal application of IFNβ protected macaques from repeated intrarectal and 
intravaginal challenges with a simian-human immunodeficiency virus (SHIV) (35). Since type 1 
IFNs are rapidly upregulated at mucosal sites of virus replication in SIVmac infected macaques 
(36), and bioactive IFN levels are highly elevated during acute HIV-1 infection (37), we 
hypothesized that IFN-mediated antiviral activity contributes to the HIV-1 transmission bottleneck. 
To test this, we generated a large panel of limiting dilution derived isolates from the plasma and 
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genital secretions of chronically infected donors and their matched recipients. Analyzing 300 such 
isolates, we identified a number of biological properties that are associated with increased 
transmission fitness, all of which serve to enhance HIV-1 replication and spread in the face of a 
vigorous innate immune response. 
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Section 2.4 – Results 
 
Generation of limiting dilution HIV-1 isolates from sexual transmission pairs. Molecular 
cloning of HIV-1 genomes is labor intensive and thus limits the number of IMCs that can 
reasonably be characterized. Moreover, predicting which viral genomes are functional in 
chronically infected individuals is challenging, because immune escape mutations frequently incur 
fitness costs (38-45). Virus isolation represents an alternative to cloning, but bulk cultures cannot 
account for the biological variation of individual quasispecies members. Here, we used limiting 
dilution virus isolation to generate single virion-derived HIV-1 strains from eight sexual 
transmission pairs. These included four female-to-male (FTM) transmissions (subtype C) from 
southern Africa as well as from one male-to-female (MTF) and three men-who-have-sex-with-
men (MSM) transmissions (subtype B) from the US (SI Appendix, Table S1). In all but one case, 
the newly infected recipient was identified first as part of an acute infection cohort, while the 
transmitting partner was identified retrospectively. Phylogenetic analysis of SGA-derived plasma 
viral sequences confirmed that all transmission pairs were epidemiologically linked (SI Appendix, 
Fig. S2.1) and showed that two recipients (CH378, CH831) had acquired their infection from the 
same donor (CH742). Seven of the eight recipients were infected with a single TF virus, while the 
remaining subject (CH378) acquired at least two TF viruses (SI Appendix, Fig. S2.2). All subjects 
remained treatment naïve throughout the study. 
 To generate limiting dilution-derived viral isolates, plasma as well as cell-free fractions of 
cervicovaginal lavage (CVL) and semen (SEM) samples were end-point diluted and used to infect 
activated normal donor CD4+ T-cells in 24 well plates. According to a Poisson distribution, a 
dilution that yields positive cultures in no more than 30% of wells should contain a single 
infectious unit more than 80% of the time. Cultures were maintained for 20 days, tested for p24 
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antigen production, and virus positive wells were expanded further in normal donor CD4+ T cells 
for an additional 10 days. The resulting viral stocks were used for all subsequent genetic and 
biological analyses.  
 To ensure that the limiting dilution isolates were indeed single virion-derived, we 
sequenced all stocks prior to biological characterization. Briefly, 5’ and 3’ half genomes were 
PCR amplified, MiSeq sequenced, and the resulting reads assembled to generate an isolate 
specific consensus sequence. Viral reads were then mapped to this consensus sequence and the 
extent of genetic diversity was examined for each position along the genome. Isolates that 
exhibited more than 15% diversity at any one position in the alignment were considered to 
contain more than one variant and thus removed from further analysis. To control for the 
emergence of phenotypically distinct variants in the culture, we generated limiting dilution isolates 
from all acutely infected subjects even though TF IMCs were available for two recipients (14, 26). 
Using plasma samples collected closest to the time of transmission, we generated 95 donor and 
61 recipient isolates (SI Appendix, Table S2.1). Virus isolation from CVL and SEM samples was 
more challenging, because of lower viral loads, frequent bacterial and yeast contaminations, and 
the fact that many genital secretions were inherently cytotoxic for CD4+ T cells (46).  
Nonetheless, we were able to generate limiting dilution isolates from the CVL or semen samples 
of three transmitting donors (SI Appendix, Table S1).  
  
Limiting dilution HIV-1 isolates are representative of the donor quasispecies. To determine 
whether the limiting dilution isolates were representative of the viral quasispecies present in both 
donors and recipients, we compared all isolate-derived sequences to SGA derived vRNA 
sequences amplified directly from the blood of the same individual. In phylogenetic trees of 3’ half 
genome sequences, isolate and plasma vRNA sequences were completely interspersed (Figs. 
2.1A and SI Appendix, Fig. S2.3). To assess whether isolate and plasma viral sequences from 
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chronically infected donors were segregated, we calculated their genealogical sorting index (gsi) 
(47). Two donor samples yielded gsi values that were higher than expected from random 
segregation (SI Appendix, Table S2.2A). In one case (CH212), available isolates represented 
only two of three diverse viral lineages present in this donor’s quasispecies, indicating limited 
sampling (SI Appendix, Fig. S2.3F). In the other case (CH728), two pairs of near identical isolate 
sequences indicated repeat culture of the same virus (SI Appendix, Fig. S2.3C). Collapsing one 
of these to a single sequence rendered the gsi value non-significant. For all other subjects, there 
was no evidence for segregation (SI Appendix, Table S2.2A), indicating that the isolates were 
fully representative of the viral diversity present in the plasma. As expected, plasma isolates from 
single TF infections were very closely related, differing from each other by fewer than 8 (range 2-
7) and from the inferred TF genome by fewer than 12 (range 2-11) nucleotides across the entire 
genome (SI Appendix, Fig. S2.2). Plasma isolates from subject CH378 exhibited greater diversity, 
because they represented the progeny of two TF viruses as well as their recombinants (SI 
Appendix, Fig. S2.2A). Unlike in some previous studies (8), there was no evidence of 
compartmentalization of plasma and genital secretion isolates from donors CH492 and CH742 (SI 
Appendix, Fig. S2.3 and Table S2.2B).   
 
Increased Env content is not a characteristic feature of transmitted viruses. Comparing 
viruses from unrelated subjects, we previously reported that TF IMCs package on average 1.9-
fold more envelope glycoprotein (Env) than viruses circulating in the plasma of chronically 
infected individuals (26). To examine the Env content of matched donor and recipient isolates, we 
generated viral stocks in normal donor CD4+ T cells, depleted these of microvesicles, purified 
virions using antibody coated magnetic beads, and quantified Env by enzyme-linked 
immunosorbent assay (ELISA) per unit of RT activity. We found that plasma isolates varied 
widely in the amounts of Env that they packaged, but failed to identify consistent differences 
between donor and recipient isolates. Recipient isolates packaged either significantly more, less, 
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or similar amounts of Env compared to their corresponding donor viruses (Figs. 2.1B and SI 
Appendix, Fig. S2.4A). For one donor (CH492), genital tract isolates had a 2.4-fold higher mean 
Env content than the corresponding plasma isolates, but this was not the case for the other two 
donors (Figs. 2.1B and SI Appendix, Fig. S2.4A). When data from all pairs were combined, no 
significant differences in Env content were observed between donor and recipient isolates, 
plasma and genital secretion isolates, and subtype B and C recipient isolates (Fig. 2.1C). These 
data indicate that mucosal transmission does not select for viruses with an increased Env 
content. 
 
Transmitted viruses exhibit increased particle infectivity. We previously reported that TF 
viruses were 2-fold more infectious than chronic viruses from unrelated subjects (26), but two 
subsequent studies failed to identify virus infectivity as a determinant of transmission fitness (27, 
28). Here, we used TZM-bl cells, which express luciferase under the control of an HIV-1 promoter 
(48, 49), to determine the per-particle infectivity of CD4+ T cell-derived viral stocks. To limit virus 
infection to a single round, we added the fusion inhibitor T1249 (50) to all cultures 12-15 hours 
following infection. Plotting relative light units (RLUs) per amount of input virus (pg of RT), we 
found that donor plasma isolates exhibited a wide range of particle infectivity both within and 
between individuals, while the infectivity of recipient isolates was much less variable. Moreover, 
for seven transmission pairs, recipient viruses were significantly (2 to 8-fold) more infectious than 
the corresponding donor viruses, with a trend observed for the eighth pair (Figs. 2.1D and SI 
Appendix, Fig. S2.4B). Higher particle infectivity relative to plasma viruses was also observed for 
CVL and SEM isolates from two donors (1.8- and 3.2-fold, respectively), but not for the third 
donor, although in the latter case only two CVL isolates were available for comparison (Fig. 2.1D 
and SI Appendix, Fig. S2.4B). When data from all transmission pairs were combined, recipient 
isolates were on average 3-fold more infectious (P = 0.0001) than the corresponding donor 
isolates irrespective of their subtype (Fig. 2.1E). Donor genital secretion isolates tended to be 
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more infectious than the corresponding plasma isolates, but this did not reach statistical 
significance. Thus, mucosal transmission selects for viruses with increased particle infectivity, 
some of which are present in genital secretions.  
 
Transmitted viruses replicate to higher titers. The replicative capacity of viruses can influence 
their reproductive ratio (R0) and thus their ability to expand an initial infection (51). Comparing 
IMCs from unrelated subjects, we previously failed to detect differences in the growth potential of 
TF and chronic HIV-1 strains (26), and similar results were reported for donor and recipient 
viruses from transmission pairs (27, 28). Here, we compared the replicative capacity of limiting 
dilution-derived isolates in normal donor CD4+ T cells.  Using equal numbers of particles for viral 
input (1 ng of RT activity), we monitored the growth kinetics of a subset of isolates (n = 25) for 9 
days by measuring p24 antigen in culture supernatants every 48 hours. We then determined the 
area under the curve (AUC) and compared it with p24 values measured at individual time points. 
This analysis revealed a strong correlation between the AUC and p24 production at day 7 (r = 
0.99, P < 0.0001). We thus used the latter as a measure of viral replicative capacity for all 
remaining isolates.  
 Transmitting donor isolates varied widely in their replicative capacity, and this was also 
true for some recipient isolates. However, recipient isolates replicated on average between 1.2 
and 1.7-fold more efficiently than viruses isolated from the corresponding donors (Figs. 2.1F and 
SI Appendix, Fig. S2.4C). These differences were significant for seven transmission pairs, with a 
trend observed for the eighth pair (Figs. 2.1F and SI Appendix, Fig. S2.4C). In contrast, genital 
secretion isolates did not exhibit an increased replicative capacity. Combining results from all 
transmission pairs, we found that on average recipient isolates grew to 1.4-fold higher titers than 
their corresponding donor isolates (P = 0.004), while no significant differences were observed 
between plasma and genital secretion isolates, or between recipient isolates representing 
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subtype B and C infections (Fig. 2.1G). These data indicate that mucosal transmission selects for 
viruses with enhanced replicative capacity.    
 
Transmitted viruses are uniformly resistant to type I interferons. We previously reported that 
TF viruses are more resistant to IFNα2 than viruses from chronically infected individuals (26, 52). 
However, two subsequent studies of linked transmission pairs failed to confirm this phenotype, 
with one study finding no differences in IFNα2 resistance between transmitted and non-
transmitted viruses (27), and the other reporting transmitted viruses being more IFNα2 sensitive 
(28). To resolve these differences, we tested the IFN sensitivity of the limiting dilution-derived 
isolates, but with some experimental modifications. First, instead of testing only IFNα2, we 
measured the antiviral effect of a second potent inhibitor of HIV-1, IFNβ (35, 52) Second, rather 
than examining the effect of only a single IFN inhibitory dose (26-28, 53), we determined the half-
maximal inhibitory concentration (IC50) of both IFNα2 and IFNβ for every single isolate.  This was 
done by treating normal donor CD4+ T cells with increasing quantities of IFN, infecting them with 
equal amounts of virus, and culturing the cells for 7 days while replenishing IFN-containing 
medium. Virus replication was then measured for each IFN concentration as the amount of p24 
produced at day 7 and plotted as the percentage of viral growth in the absence of IFN, which was 
set to 100% (Fig. 2.2A and B). As an independent measure of IFN resistance, we also measured 
viral replication at the highest IFN dose and expressed this residual replication capacity (Vres) as 
the percentage of viral growth in the absence of IFN (Fig. 2.2A and B, SI Appendix, Fig. S2.5B 
and D).   
 For each transmission pair, plasma isolates from donors exhibited a wide range of 
sensitivities to both IFNα2 and IFNβ, while recipient isolates were much less variable as well as 
uniformly more resistant to both IFNα2 and IFNβ (Fig. 2.2C and E). Compared to the respective 
donor isolates, recipient isolates exhibited on average 6- to 11-fold higher IFNα2, and 15- to 71-
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fold higher IFNβ IC50 values (SI Appendix, Fig. S2.5A and C). Analysis of the residual replicative 
capacity, Vres, yielded similar results, although the differences between donor and recipient 
isolates were much more pronounced. At the highest IFNα2 dose (5.5 pg/ml), recipient isolates 
retained on average 15% to 26% of their replicative capacity, while the corresponding donor 
viruses reached only 0.8% to 2% (SI Appendix, Fig. S2.5B). At the highest IFNβ dose (0.44 
pg/ml), recipient viruses retained on average 4% to 13% of their replicative capacity, while the 
corresponding donor isolates were either suppressed below the limits of p24 detection or reached 
Vres values of 0.01% to 0.1% (SI Appendix, Fig. S2.5D). Thus, the ability of recipient isolates to 
replicate at the highest IFN dose was 13- to 51-fold higher for IFNα2, and 123- to 541-fold higher 
for IFNβ, compared to the corresponding donor viruses (SI Appendix, Fig. S2.5B and D).  
 Examining genital tract isolates, we found that they also exhibited higher IFNα2 and IFNβ 
IC50 values than the corresponding plasma isolates, although significance was reached only for 
IFNβ (P = 0.04) (Fig. 2.2F). In addition, genital tract isolates exhibited higher Vres values, but in 
this case significance was reached only for IFNα2 (P = 0.008) (SI Appendix, Fig. S2.6B). 
Comparing IC50 and Vres, we found that these values correlated strongly for donor plasma 
isolates (IFNα2: r = 0.89, P < 0.0001; IFNβ: r = 0.57, P < 0.0001), but only weakly for donor 
genital secretion isolates (IFNα2: r = 0.34, P < 0.05; IFNβ: r = 0.40, P < 0.01), indicating that IC50 
and Vres provide different measures of the antiviral effect of IFNs in these compartments. 
Similarly, IC50 values for IFNα2 and IFNβ correlated only weakly (r = 0.33, P = 0.048), indicating 
only a partial overlap in the effects of the two IFN subtypes on the activation state, survival, and 
ISG expression levels of CD4+ T cells.  
 Combining data from all transmission pairs, we found that recipient isolates were on 
average significantly more resistant to both IFNα2 and IFNβ than the corresponding donor 
isolates, exhibiting 7.8-fold (P < 0.00001) and 39-fold (P < 0.00001) higher IC50 values, 
respectively (Fig. 2.2D and F).  Moreover, recipient isolates had 35-fold (P < 0.00001) and 250-
fold (P < 0.00001) greater odds of replicating at the highest IFNα2 (SI Appendix, Fig. S2.6B) and 
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IFNβ (SI Appendix, Fig. S2.6D) doses than the great majority of donor viruses, respectively. 
These differences were not dependent on the viral subtype (Fig. 2.2D and F). Thus, resistance to 
type 1 IFNs is a characteristic feature of transmitted viruses.   
 
Selection with IFNβ, but not IFNα2, yields donor isolates with a transmitted virus-like 
phenotype. To search for IFN resistant viruses in donor plasma, we treated CD4+ T-cells with 
high doses of IFNα2 (4.0 pg/ml) or IFNβ (0.44 ng/ml) 24 hours prior to virus isolation. The 
rationale was to maximally upregulate antiviral ISGs in these target cells (without causing cell 
toxicity), thereby simulating, at least in part, conditions during the earliest stages of HIV-1 
infection. As a control, the same approach was used to isolate viruses from recipient plasma. As 
expected, the number of viral isolates recovered from pretreated CD4+ T cells was lower than 
from untreated CD4+ T cells, especially when IFNβ was used for selection (SI Appendix, Table 
S1). Thus, while IFNα2 pretreatment yielded plasma isolates for all donors and recipients, only 
three donors and two recipients yielded IFNβ preselected plasma isolates. This was as expected 
since the selection dose of IFNβ was six orders of magnitude higher than the average IFNβ IC50 
value of all isolates (IFNα2 doses higher than 5.5 pg/ml caused cell toxicity). Phylogenetic 
analyses of full-length genome sequences revealed no evidence of compartmentalization of 
selected and non-selected isolates (SI Appendix, Fig. S2.7, Table S2.2C).  
 IC50 determinations confirmed that donor isolates from IFN pretreated cells were indeed 
more IFN resistant than those derived from untreated CD4+ T cells, while no changes were 
observed for recipient isolates (Fig. 2.3).  For example, IFNα2- and IFNβ-selected plasma 
isolates from donor CH492 had mean IFNα2 and IFNβ IC50 values than were 7.6-fold and 31-fold 
higher than those of untreated plasma isolates (Fig. 2.3A and C). However, resistance to one IFN 
subtype did not always predict resistance to the other. For donor CH492, IFNβ pretreatment 
generated isolates that were also highly resistant to IFNα2 (Fig. 2.3A), while IFNα2 pretreatment 
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generated isolates with a wide range of IFNβ IC50 values, including some as low as untreated 
isolates (Fig. 2.3C). When results from all donors were combined, both IFNα2- and IFNβ-selected 
isolates were as resistant to IFNα2 as were untreated recipient isolates (Fig. 2.3B). In contrast, 
IFNα2-selected isolates were 7-fold less resistant to IFNβ than IFNβ-selected isolates, and these 
in turn were 2-fold less resistant than untreated recipient isolates (Fig. 2.3D). Similar results were 
obtained for Vres, which showed that IFNα2 selection did not generally yield IFNβ resistant 
isolates, and that IFNβ selected isolates were less resistant to IFNβ than untreated recipient 
isolates (SI Appendix, Fig. S2.6). Interestingly, IFN selection did not increase the IC50 or Vres 
values of recipient isolates, suggesting that transmitted viruses are already maximally resistant to 
both of these IFN subtypes (Fig. 2.3B and D; SI Appendix, Fig. S2.6B and D).  
 Having generated IFNα2 or IFNβ preselected isolates, we next examined their biological 
properties. For donor CH492, IFNα2 and IFNβ pretreatment resulted in isolates that packaged 
2.0- and 3.3-fold more Env than untreated isolates, respectively (Fig. 2.3E). However, no 
significant differences in Env content were detected between treated and untreated isolates when 
data from all subjects were combined (Fig. 2.3F). However, pretreatment with IFNα2 and IFNβ 
resulted in donor isolates that exhibited increased infectivity. This was observed for donor CH492 
(Fig. 2.3G) as well as all donor isolates combined (Fig. 3H). IFNα2 and IFNβ pretreatment yielded 
plasma isolates that were on average 2- and 2.2-fold more infectious, respectively, than isolates 
obtained without selection, although neither pretreated group was as infectious as the recipient 
isolates. Interestingly, IFN pretreatment had no effect on the infectivity of recipient isolates (Fig. 
2.3H).   
 Reasoning that IFN pretreatment may favor the outgrowth of viruses that replicated to 
higher titers, we compared the replicative capacity of IFN-selected and unselected donor and 
recipient isolates. Indeed, pretreatment of CD4+ target cells with IFNβ resulted in donor isolates 
that replicated more efficiently than untreated viruses, both for CH492 (1.3-fold; Fig. 2.3I) and all 
donor isolates combined (1.3-fold; Fig. 2.3J). However, this was not observed when CD4+ T cells 
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were pretreated with IFNα2. Surprisingly, IFNα2-selected isolates replicated significantly less 
well, both for donor CH492 (1.7-fold; Fig. 2.3I) and all donor isolates combined (2.1-fold; Fig. 
2.3J). For each of the seven donors, IFNα2 treatment selected isolates whose replicative capacity 
was much reduced compared to untreated isolates despite higher infectivity and in some cases 
greater amounts of packaged Env (e.g., CH492). These data indicate that IFNα2 and IFNβ 
selection can have opposing effects on some viral properties, and that in contrast to previous 
suggestions (27), IFN resistance is not simply a consequence of a higher replicative fitness. As 
expected, IFNα2 and IFNβ selection did not increase the growth potential of recipient isolates 
(Fig. 2.3J). Taken together, these results indicate that both IFNα2 and IFNβ resistant viruses are 
present, albeit at low levels, in the plasma of chronically infected individuals, and that in vitro 
treatment of CD4+ T cells with IFNβ, but not IFNα2, selects isolates that approach the phenotype 
of transmitted viruses (Figs. 2.3 and SI Appendix, Fig. S2.6). 
 
Transmitted viruses are more efficiently released from infected cells. We previously 
reported that CD4+ T cells infected with TF viruses released larger quantities of cell-free virions 
than cultures infected with CC viruses (54). However, since only two TF and two CC IMCs were 
studied, we examined this property in a much larger number (n = 127) of matched donor and 
recipient isolates. To quantify particle release from infected CD4+ T cells, we measured the 
amounts of cell-free and cell-associated p24 antigen seven days post-infection, and used these 
values to calculate the percentage of p24 that was released into the supernatant. Consistent with 
our previous observations (54), we found that donor isolates produced on average much less cell-
free virus than recipient isolates (Fig. 2.4), although the total amount of p24 in these cultures was 
comparable. Plasma and genital secretion isolates from chronically infected donors released on 
average 31% and 38% of their total p24, respectively, while recipient isolates released 65%. In 
addition, IFN selected isolates released more p24 than unselected donor isolates, although this 
effect was less pronounced for IFNα2 (42%) than for IFNβ (64%). Combining results from all 
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isolates, the odds of p24 antigen being released from CD4+ T cell cultures infected with IFNα2- 
and IFNβ-selected donor isolates were 1.6-fold and 3.8-fold higher, respectively, than from 
cultures infected with untreated donor isolates, and the odds of release were even higher (4.2-
fold) for untreated recipient isolates (Fig. 2.4B). In contrast, no differences were observed for 
donor genital secretion isolates as well as for IFN-treated and untreated recipient isolates (Fig. 
2.4B). Thus, mucosal transmission selects for viruses with a significantly enhanced particle 
release capacity, suggesting that the production of cell-free virions is important in the 
transmission process. 
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Section 2.5 – Discussion 
 
An effective AIDS vaccine will need to prevent acquisition of HIV-1 at mucosal surfaces (5).  In 
this context, it is critical to know whether transmitted viruses possess unique biological properties 
that predispose them to establish new infections more efficiently. This is a controversial topic, 
since some studies have reported TF-specific traits (22, 24, 26, 52, 55-57), while others have 
failed to confirm these results (27, 28, 53, 58, 59). Some of these discrepancies are likely due to 
the fact that most previous analyses did not compare HIV-1 strains from transmission pairs. Using 
a more rigorous approach, two recent studies characterized viruses from matched donors and 
recipients, but failed to identify viral properties that were indicative of enhanced transmission 
fitness (27, 28).  These findings led to the prevailing view that HIV-1 transmission is a stochastic 
process in which any reasonably fit virus has the potential of crossing the mucosa.  
 Both transmission pair studies characterized only very few donor and recipient viruses, 
using either infectious molecular clones (27) or PBMC-derived bulk cultures (28). Reasoning that 
this approach had likely led to erroneous conclusions, we used limiting dilution isolation to 
generate a much larger number of donor and recipient viruses for phenotypic comparisons. We 
also used plasma rather than PBMCs for virus isolation to preclude the characterization of 
archived HIV-1 strains, generated genital secretion isolates for a subset of donors, and examined 
viral properties, such as virion release and resistance to IFNβ, which have not previously been 
characterized.  Finally, we rendered the CD4+ T cells used for virus isolation more resistant to 
infection by treating them with high doses of type 1 IFNs to simulate host innate defenses that 
may be operative during the earliest stages of infection. We found that both recipient and in vitro 
IFN-selected donor isolates were more infectious, replicated to higher titers, were released from 
infected cells more efficiently, and were much more resistant to both IFNα2 and IFNβ than the 
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great majority of unselected donor isolates (Figs. 2.1-4). Thus, it seems clear that these viral 
properties collectively contribute to transmission fitness.  
 To visualize the biological properties examined for all virus isolates (particle Env content, 
infectivity, replicative capacity, IFN IC50 and Vres values) in combination, we conducted a 
principal component analysis (Fig. 2.5A and B). This approach revealed two major groups, one 
that contained all plasma and genital secretion isolates from chronically infected donors, and 
another that included all plasma isolates from acutely infected recipients (Fig. 2.5A). The fact that 
there was no overlap between these groups indicates that transmitted viruses are phenotypically 
distinct. This conclusion was confirmed when IFN-treated isolates were plotted on the same 
principal components (Fig. 2.5B). While most IFNα2 selected donor isolates grouped within the 
untreated donor cluster, most IFNβ selected donor isolates overlapped the cluster of recipient 
viruses (Fig. 2.5B).  
 To quantify these relationships, we calculated the distance between each virus and its 
pair-matched recipient average of the first two principal components (Fig. 2.5C). As expected, 
untreated and IFN treated recipient isolates were the closest to the recipient average, exhibiting 
only minimal variation. In contrast, untreated donor plasma and genital secretion isolates as well 
as IFNα2-selected donor isolates were most distant from the average position of their respective 
recipient isolates and exhibited a wide distribution of distances. Interestingly, IFNβ-selected donor 
isolates were much closer to their recipient isolate average, consistent with IFNβ selection 
yielding a transmitted virus-like phenotype. We also examined the accuracy with which an isolate 
could be predicted to be derived from either a donor or a recipient on the basis of the seven 
biological properties examined (Fig. 2.5D). This analysis showed that IFN IC50 and Vres values 
predicted donor and recipient isolates with near 100% accuracy, indicating that resistance to type 
1 IFNs is the most distinguishing characteristic of transmitted viruses. 
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 If IFN resistance represents such a discerning feature, why did previous transmission pair 
studies miss this property? As shown in Fig. 2.2, chronic viruses exhibit a wide range of IFN IC50 
values, indicating that random selection of just two such viruses per transmitting donor as 
reported by Deymier et al (27) may not reveal donor/recipient differences. Moreover, measuring 
viral inhibition in response to a single IFN dose (26-28, 53) is likely less accurate than a formal 
IC50 determination. It should also be noted that the resistance of HIV-1 to IFNs is not constant 
during the course of infection. IFN resistance declines rapidly within the first six months (52, 57), 
but then increases again when subjects progress toward AIDS (52, 60, 61). Thus, depending 
when during the course of infection a virus is transmitted to another person, donor viruses may be 
more or less IFN resistant. For example, viruses from donors who transmit during acute HIV-1 
infection or immediately following treatment interruption as described by Oberle et al (28) would 
be expected to exhibit much higher levels of IFN resistance than viruses from subjects who 
transmit during asymptomatic chronic infection. In addition, PBMC cultures may reactivate latent 
viruses, which would be expected to exhibit IFN resistance levels consistent with their entry into 
the latent pool.  
 None of the previous transmission pair studies analyzed viral resistance to IFNβ, which 
produced the most pronounced donor/recipient differences. Indeed, the 39-fold higher IFNβ IC50 
values of recipient isolates (Fig. 2.2F) is likely a gross underestimate, since many donor viruses 
were already more than 50% inhibited at the lowest IFNβ dose (Fig. 2.2B). This explains why the 
donor/recipient differences for IFNβ Vres values are so much higher than the corresponding IC50 
values, and why this is not observed for IFNα2 (Figs. 2.2F and SI Appendix, Fig. S2.5D). While 
both IC50 and Vres values provide an indicator of IFN resistance, they seem to describe only 
partially overlapping biological effects. For example, the strong correlation of both IFNα2 and 
IFNβ IC50 and Vres values for donor plasma isolates likely indicates restriction by an IFN dose-
driven increase in interferon stimulated gene (ISG) activity. In contrast, the lack of a similarly 
strong correlation for donor genital secretion isolates suggests that some of these viruses are 
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restricted by ISGs whose inhibitory activity is not IFN dose dependent. In addition, Vres may be a 
more relevant indicator of IFN resistance during the acute phase of infection when IFN levels are 
particularly high in the mucosa, while IC50 may be a more appropriate measure of systemic 
immune activation during later stages of infection. Future studies will need to determine the full 
range of IFNα2 and IFNβ IC50 and Vres values in HIV-1 infected subjects over time. 
 Not all viral properties studied contributed, or contributed equally, to HIV-1 transmission 
fitness. For example, virion associated Env content, although previously identified as a 
characteristic feature of TF viruses (26), did not differentiate donor and recipient isolates (Figs. 
2.1C and 2.5D). Nonetheless, in half of the transmission pairs studied, recipient isolates 
packaged significantly more Env than the respective donor viruses (Fig. 2.1B), suggesting that 
increased Env content may increase transmission fitness under certain circumstances. Similarly, 
particle infectivity and replicative capacity were significantly increased in most, but not all, 
recipient isolates. The successful transmission of viruses lacking these properties suggests that 
they are not absolutely required and/or that their absence can be compensated by other factors. 
In contrast, enhanced resistance to type I IFNs was observed for every single recipient isolate, 
indicating that the ability to counteract these innate immune responses is essential for successful 
mucosal transmission.  
The need to overcome innate defenses is also exemplified by the fact that recipient and 
IFNβ-selected donor isolates produced much higher levels of cell-free virus than the 
corresponding untreated donor isolates (Fig. 2.4). Type 1 IFNs induce tetherin, which prevents 
the release of virus particles from the plasma membrane of infected cells. HIV-1 counteracts 
tetherin using its Vpu protein, which binds tetherin and prevents its expression on the cell surface 
(62-64). However, TF Vpu proteins do not seem to counteract tetherin more effectively than the 
Vpu protein of chronic viruses (65). Moreover, TF infected CD4 T cells were shown to produce 
more cell free virions even in the absence of Vpu (54). Although we have not mapped the 
genomic region(s) responsible for the significantly enhanced virion release capacity of recipient 
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isolates, it is unlikely that Vpu alone is responsible. In fact, several isolates that differed 
significantly in their particle release function encoded identical vpu genes (SI Appendix, Fig. 
S2.7). Thus, it seems clear that other as-yet-unknown factors must be responsible for the 
increased particle release function of recipient (and IFNβ-selected donor) isolates, which may be 
critical to enhance virus spread in the mucosa during the first rounds of replication when 
extracellular IFN levels are particularly high. 
 In summary, we have identified resistance to type 1 IFNs, in particular IFNβ, as a key 
determinant of HIV-1 transmission fitness. This observation is consistent with previous studies 
showing that innate responses in the mucosa immediately following infection are inducing a 
potent antiviral state through the upregulation of ISGs, many of which have anti-HIV-1 activity (63, 
64, 66-73). All IFN subtypes signal through the same heterodimeric receptor (30), but differences 
in receptor binding and/or downstream signal transduction pathways are thought to be 
responsible for IFN subtype-specific biological effects (74-77). IFNβ has been reported to bind the 
IFN receptor (IFNAR) with the highest affinity (76) and ligates the IFNAR1 chain in an IFNAR2-
independent manner, resulting in the expression of a distinct set of genes (78). Either of these 
properties could explain its greater potency in placing selection on the transmitted virus pool. 
Nonetheless, IFNβ selection did not fully recapitulate the biological properties of recipient isolates 
despite the extremely high dose that was used to treat the target cells (Figs. 2.3D, 5B, 5C and SI 
Appendix, Fig. S2.6D). These results indicate that additional factors, possibly including IFNα2 
and/or other IFN subtypes, shape the transmitted founder phenotype. Since there are a total of 13 
IFNα subtypes as well as other type 1 IFNs such as IFNω, some of which inhibit HIV-1 even more 
potently in vitro and in animal models (79-81), it will be critical to evaluate to what extent they 
contribute alone, or in combination, to the HIV-1 transmission bottleneck.  
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Section 2.8 – Chapter Figures  
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Fig. 2.1. Genetic and biological characterization of matched donor and recipient limiting 
dilution-derived isolates. (A) The phylogenetic relationships of donor (green) and recipient 
(brown) isolate sequences to donor (blue) and recipient (red) SGA-derived plasma viral 
sequences are shown for the CH596-CH455 transmission pair (maximum likelihood trees for all 
other transmission pairs are shown in SI Appendix, Fig. S2.3). Asterisks denote nodes with 100% 
bootstrap support (the scale bar indicates 0.01 substitutions per site). (B, D, F) Viral Env content 
(mass ratio of gp120 and RT), particle infectivity (relative light units [RLU] in TZM-bl cells per 
picogram of RT), and replicative capacity (p24 antigen levels in CD4+ T cell culture supernatants 
seven days post-infection) of plasma isolates from matched donor (D) and recipient (R) pairs 
(color-coded) are shown, with HIV-1 subtype classification indicated below. Data are grouped for 
each transmission pair, with genital secretion isolates (GS) shown as hashed boxes. Donor D-
CH472 transmitted to two recipients R-CH378 and R-CH831. Boxes show the interquartile range, 
a black bar within each box indicates the geometric mean, and whiskers span the range of the 
data, respectively. Asterisks indicate significant differences (determined by unpaired t-test) 
between groups (* p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001). (C, E, G) A hierarchical 
Bayesian regression model was used to estimate the population-wide fold change of Env content 
(C), particle infectivity (E), and replicative capacity (G) across all transmission pairs between 
donor and recipient plasma isolates (red), donor plasma and genital (Gen.) secretion isolates 
(blue), and clade B and C recipient isolates (green). A dashed line indicates a fold change of 1, 
indicating no effect. The estimated posterior probability distribution for each parameter is shown 
along with a table summarizing the expected fold change and the probability that the effect is less 
than 1 (analogous to a one-sided p-value). 
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Fig. 2.2. IFN resistance of matched donor and recipient isolates. (A, B) Dose response 
curves for IFNα2 (A) and IFNβ (B) are shown for plasma (green) and genital secretion (magenta) 
isolates of one chronically infected donor as well as plasma isolates of the corresponding acutely 
infected recipient (red) of a representative transmission pair (CH492-CH427). A black line 
indicates the half-maximal inhibitory concentration (IC50), and a double arrow the residual viral 
replication (Vres) capacity at the highest IFN dose. (C, E) IFNα2 (C) and IFNβ (E) concentrations 
(picograms per ml), which resulted in 50% viral inhibition, are shown for plasma isolates from 
matched donor (D) and recipient (R) pairs (color-coded as in Fig. 2.1), with HIV-1 subtype 
classification indicated below. Data are grouped for each transmission pair, with genital secretion 
isolates (GS) shown as hashed boxes. Donor D-CH472 transmitted to two recipients R-CH378 
and R-CH831. Boxes show the interquartile range, a black bar within each box indicates the 
geometric mean, and whiskers span the range of the data, respectively. Asterisks indicate 
significant differences (determined by unpaired t-test) between groups (* p < 0.05; ** p < 0.01; *** 
p < 0.001; **** p < 0.0001). IFN IC50 values were determined in pooled CD4+ T-cells from multiple 
donors. (D, F) A hierarchical Bayesian regression model was used to estimate the population-
wide fold change of IFNα2 (D) and IFNβ (F) IC50 values across all transmission pairs between 
donor and recipient plasma isolates (red), donor plasma and genital (Gen.) secretion isolates 
(blue), and clade B and C recipient isolates (green). A dashed vertical line marks a fold change of 
1 indicating no effect. The estimated posterior probability distribution for each parameter is shown 
along with a table summarizing the expected fold change and the probability that the effect is less 
than 1 (analogous to a one-sided p-value). 
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Fig. 2.3. Biological characterization of IFNα2- and IFNβ-selected donor and recipient  
isolates. (A, C, E, G, I) IFNα2 IC50 (picogram per ml) (A), IFNβ IC50 (picogram per ml) (C), viral 
Env content (mass ratio of gp120 and RT) (E), particle infectivity (RLU per picogram of RT) (G), 
and replicative capacity in CD4+ T cells (ng of p24 antigen per ml) (I) values are shown for 
limiting dilution derived viral isolates from one representative matched donor (D-CH492) and 
recipient (R-CH427) pair. In each panel, untreated (dark green), IFNα2-selected (light green), and 
IFNβ−selected (yellow) isolates from the donor (D-492) are compared to untreated (red), IFNα2-
selected (dark pink) and IFNβ-selected (light pink) isolates from the corresponding recipient R-
CH427. Boxes show the interquartile range, a black bar within each box indicates the geometric 
mean and whiskers span the range of the data, respectively. Asterisks indicate significant 
differences (determined by unpaired t-test) between groups (* p < 0.05; ** p < 0.01; *** p < 0.001; 
**** p < 0.0001). Since IFN selection did not alter the phenotype of recipient isolates, only 
statistical comparisons of donor isolates to untreated recipient isolates are shown. (B, D, F, H, J) 
A hierarchical Bayesian regression model was used to estimate the population-wide fold change 
of IFNα2 IC50 (B), IFNβ IC50 (D), Env content (F), particle infectivity (H), and replicative capacity in 
CD4+ T cells (J) across all transmission pairs between untreated and IFNα2-selected donor 
isolates (blue), untreated and IFNβ-selected donor isolates (green), untreated and IFNα2-
selected recipient isolates (grey), and untreated and IFNβ-selected recipient isolates (yellow). 
The fold change between untreated donor and recipient plasma isolates (red), as in Figs. 2.1 and 
2.2, is also shown for comparison. A dashed vertical line marks a fold change of 1 indicating no 
effect. The estimated posterior probability distribution for each parameter is shown along with a 
table summarizing the expected fold change and the probability that the effect is less than 1 (or 
where indicated by an asterisk (*) the probability that the effect is greater than 1). 
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Fig. 2.4. Particle release capacity of matched donor and recipient isolates.  (A) Donor and 
recipient isolates were tested for their ability to be released from infected CD4+ T cells. The 
percent of viral release was determined as the ratio of cell-free p24 divided by the total amount 
(cell-associated plus cell-free) of p24 seven days post-infection. Only a subset of isolates (n = 
132) was tested. Values are color coded by transmission pair. (B) A hierarchical Bayesian 
regression model was used to estimate the population-wide fold change in the odds of release 
(the probability of release divided by the probability of retention) of p24 between untreated and 
IFNα2-selected donor plasma isolates (blue), untreated and IFNβ-selected donor plasma isolates 
(green), untreated donor plasma and genital secretion isolates (purple), untreated donor and 
recipient plasma isolates (red), untreated and IFNα2 selected recipient isolates (grey), and 
untreated and IFNβ-selected recipient isolates (yellow). A dashed vertical line marks a fold 
change of 1 indicating no effect. The estimated posterior probability distribution for each 
parameter is shown along with a table summarizing the expected fold change and the probability 
that the effect is less than 1 (analogous to a one-sided p-value). 
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Fig. 2.5. Phenotypic properties distinguishing donor and recipient isolates. (A) A principal 
component analysis was used to visualize properties that were determined for all viral isolates 
(Env content, particle infectivity, replicative capacity, IFNα2 IC50, IFNβ IC50, IFNα2 Vres and IFNβ 
Vres) in combination. The positions of untreated donor plasma (green), donor genital secretion 
(purple) and recipient plasma (red) isolates are shown on the first two components. Length and 
direction of arrows show how each variable contributes to the two axes. The minimum spanning 
ellipses that contain all data points for each group are shown in corresponding colors. (B) To 
visualize the effect of IFN-selection, IFNα2-selected (green) and IFNβ-selected (yellow) donor 
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isolates are plotted together with IFNα2-selected (dark pink) and IFNβ-selected (light pink) 
recipient isolates on the same principal components as in A. Minimum spanning ellipses 
encompassing the untreated donor plasma isolates (green), donor genital secretion isolates 
(purple) and untreated recipient plasma isolates (red) as shown in A were retained. (C) To 
quantify the groupings apparent in A and B, we calculated the distance of the first two principal 
components for each isolate to the average position of the corresponding untreated recipient 
isolates for that transmission pair. Isolates are color-coded by transmission pairs and grouped as 
in A and B. (D) The accuracy with which the seven viral properties predicted whether an isolate 
came from a donor or recipient was measured using receiver operating characteristic curves. 
Each line indicates the trade-off between true and false positive rate as a threshold is moved 
through the range of the data. Shading indicates the 95% confidence interval of the true positive 
rate. The dashed line indicates the expected performance of a predictor with no relationship to 
donor-recipient status. A line that reaches a true positive rate of 100% with a 0% false positive 
rate indicates that there is perfect separation between donor and recipient isolates. 
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Section 2. 9 – Supplemental Information and Materials Methods  
 
Study subjects. Plasma samples were obtained for seven chronically HIV-1 infected transmitting 
donors and eight matched acutely infected recipients enrolled in the CHAVI-001 acute and 
established HIV-1 infection cohorts (1). A summary of available epidemiological, clinical and 
infection status data is shown in Table S1.  In all but one case, acutely infected individuals were 
identified first and staged using the Fiebig classification (2), while the transmitting partners were 
identified retrospectively. Epidemiological linkage was confirmed through viral sequence analysis, 
which also indicated considerable quasispecies diversity in all transmitting donors except 
CH1064, who may have transmitted during earlier stages of infection (Fig. S2.1). Transmission 
pairs were selected based on the following criteria: (i) high transmitting donor plasma viral loads 
(generally >100,000 vRNA copies/ml) to increase the likelihood of obtaining virus isolates, (ii) 
availability of donor genital secretions within a year following transmission, (iii) single transmitted 
founder infections of the recipients to ensure a stringent mucosal bottleneck (one recipient was 
subsequently found to harbor two transmitted founder viruses), and (iv) absence of antiretroviral 
treatment. Whole blood was collected in acid citrate dextrose, and plasma was separated and 
stored at −80°C. In addition, cell-free fractions of genital secretions (GS) were obtained from five 
of the seven donors. Ectocervicovaginal lavage (CVL) was performed on non-menstruating 
women using 10 ml of phosphate buffered saline (PBS). Semen ejaculate was collected in 2.5ml 
of transport medium (RPMI 1640, 1,000 U/ml penicillin, 1 mg/ml streptomycin, 200U/ml nystatin).  
Genital secretion samples were centrifuged for 10 min at 800g to pellet cells; supernatants were 
harvested, aliquoted and stored at -80˚C. Written informed consent was obtained from each 
subject and the study was approved by the Institutional Review Boards of the University of 
Pennsylvania and Duke University. 
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Human CD4+ T-cell isolation and activation. CD4+ T-cells were positively selected from buffy 
coats of normal subjects (Research Blood Component, Boston, MA or ZenBio Inc., Research 
Triangle Park, NC) using Human CD4 Microbeads (Miltenyi Biotec Inc., San Diego, CA), viably 
frozen in CryoStor® CS5 medium (Sigma-Aldrich, St Louis, MO), and stored in liquid nitrogen.  
Cell aliquots were thawed quickly in a 37°C water bath, resuspended at a density of 2×106 
cells/ml, and allowed to recover overnight in RPMI 1640 medium containing 15% (vol/vol) fetal 
bovine serum (FBS) and 30 IU/mL interleukin-2 (IL-2) (CD4+ T-cell medium) in a 37°C incubator 
with 5% (vol/vol) CO2. Cells were stimulated using the Human T Cell Activation/Expansion Kit 
(Miltenyi Biotec Inc., San Diego, CA) and expanded for 4-5 days in CD4+ T-cell medium following 
the manufacturer’s protocol.  
 
Interferons and cytokines. IFNα2 was purchased from PBL Assay Science (Piscataway, NJ). 
IFNβ was purchased from PBL Assay Science and EMD Serono USA (Rebif®, EMD Serono Inc., 
Rockland, MD).  Interleukin-2 was purchased from the Hospital of the University of Pennsylvania 
pharmacy (Aldesleukin). 
 
Virus quantification. Viral stocks were characterized by determining their reverse transcriptase 
(RT) activity using the colorimetric Reverse Transcriptase Assay (Sigma-Aldrich, St Louis, MO), 
and their p24 antigen content was determined using the HIV p24 (high sensitivity) AlphaLISA 
Detection Kit (Perkin Elmer Inc., Boston, MA). 
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Generation of limiting dilution-derived HIV-1 isolates. To generate limiting dilution-derived 
viral isolates, plasma samples were end-point diluted and used to infect activated normal donor 
CD4+ T-cells in 24 well plates such that no more than 30% of wells became p24 antigen positive. 
Assuming that approximately one virus per 1,000 particles is infectious, we started with ~500 
vRNA copies/well. Plasma aliquots containing ~12,500 vRNA copies were diluted in 1ml of CD4+ 
T-cell medium containing 50µl of HIV Infectivity Enhancement Reagent (Miltenyi Biotec Inc., San 
Diego, CA). To allow the formation of HIV-1 enhancement complexes, tubes were placed on a 
MACSmix Tubes Rotator (Miltenyi Biotec Inc., San Diego, CA) and incubated at 4˚C under 
constant rotation at 4 rpm for 30 min. Activated CD4+ T-cells were seeded (1x106 per well) in a 
24-well plate in 500µl of fresh CD4+ T-cell medium; 40µl of the complex-containing solution were 
added to each well (500 vRNA copies/well), incubated for 12-16 hours in a 37°C incubator with 
5% (vol/vol) CO2, and then supplemented with an additional 1ml of T-cell medium. At days 5, 10 
and 15, activated CD4+ T-cells (1x106 in 500µl of T-cell medium) were added to each well to 
provide new target cells for virus replication. At day 20, p24 positive wells were identified using 
the HIV p24 (high sensitivity) AlphaLISA detection kit (Perkin Elmer Inc., Boston, MA). For some 
plasma samples the number of vRNA copies per well had to be adjusted to reach limiting-dilution 
conditions. These values ranged between 3 vRNA copies/well (CH831) to 2,000 vRNA 
copies/well (CH040), indicating a wide range of per particle infectivity, including in acute infection 
plasmas.  
Low viral loads in plasma samples from subjects CH162, CH728 and CH302 (Table S1) 
required larger volumes of plasma to reach the target dose of 500 vRNA copies per well.  These 
larger volumes decreased cell viability during the first incubation step of the isolation procedure. 
We thus purified the same amount of virus particles from these samples prior to infection using 
the µMACS VitalVirus HIV Isolation Kit (Miltenyi Biotec Inc., San Diego, CA).  Virus-microbead 
complexes were eluted from µ-Columns in 1ml of T-cell medium and 40µl were added to each 
well (500 vRNA copies/well) of activated target T-cells as described above. 
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To generate IFN resistant virus isolates, activated CD4+ T-cells were pre-treated with 4.0 
pg/ml of IFNα2 or 44 ng/ml of IFNβ for 24 hours prior to isolation with no further addition of IFN.  
The rationale was to maximally upregulate antiviral ISGs in these target cells, but to then isolate 
virus in the absence of interferon. For IFNβ, we were able to use a selection dose that was six 
orders of magnitude higher than the average IFNβ IC50 value of all isolates. However, this was 
not possible for IFNα2 since doses higher than 5.5 pg/ml caused toxicity in the culture. Thus, 
IFNα2 pretreatment was kept at 4.0 pg/ml. Following treatment, cells were washed once in T-cell 
medium before being plated in 24-well plates as described above.  
For virus isolation from CVL and semen samples, aliquots were thawed at room 
temperature, fetal bovine serum was added to a final concentration of 2%, and virus isolation was 
performed as described above. Since virus load information was not available, 1ml aliquots were 
used per well for one 24-well isolation plate. To inhibit the growth of bacteria, yeast and fungi, T-
cell medium was supplemented with penicillin (100 units/ml), streptomycin (100 µg/ml), and 
Amphotericin B (0.25 µg/ml) (Gibco® Antibiotic-Antimycotic, ThermoFisher Scientific, Waltham, 
MA). While isolation attempts from all plasma samples were successful, the efficiency of isolation 
from genital secretion samples was variable: only 1 of 4 CVL samples from donor CH492, 1 of 2 
CVL samples from donor CH596, and 4 of 5 semen samples from donor CH742 yielded isolates 
(Table S1).  In contrast, none of 4 CVL and semen samples from donors CH1064 and CH728, 
respectively, yielded isolates (Table S1).  
 
Virus stock preparation and genotyping. Cells and supernatants from p24 positive wells were 
transferred to T25 flasks containing 10x106 activated T-cells in 10ml of fresh T-cell medium.  After 
5 days of culture, an additional 10x106 activated T-cells in 10ml of fresh T-cell medium were 
added to each flask. At day 10 post-infection, virus-containing supernatant was passed through a 
0.45µm nylon membrane syringe filter (Corning, NY) and stored in aliquots at -80˚C.  
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To sequence each expanded virus isolate prior to its biological characterization, viral 
RNA was extracted from 100µl of culture supernatant, reverse-transcribed using SuperScript III 
Reverse Transcriptase (ThermoFisher Scientific, Waltham, MA) and previously published primers 
(3, 4), and the resulting cDNA was used to amplify overlapping 5’ and 3’ genome halves in 
separate triplicate PCR reactions as described (3-5). Ten nanograms (1µl of a 1/25 dilution of the 
PCR reaction) of each of the 5’ and 3’ amplicons were then pooled and sequenced using an 
Illumina NGS platform.  DNA libraries were prepared using the Nextera DNA Library Preparation 
Kit (Illumina Inc, San Diego, CA), as previously described (6, 7) with minor modifications.  Briefly, 
amplicons were fragmented using Nextera tagmentation buffers TD and TDE1 in a final volume of 
2.5µl. The tagmentation reaction was subjected to two rounds of PCR amplification using the 
KAPA Library Amplification Kit (Kapa Biosystems Inc., Wilmington, MA). The first round of PCR 
incorporated Index 1 (N7xx) and Index 2 (S5xx) adapters (final volume 7.5µl; 98°C for 3 min 
followed by 8 cycles, 98°C for 15 sec, 62°C for 30 sec, 72°C for 1.5 min); the second round of 
PCR (final volume 17µl; 95°C for 5 min followed by 7 cycles, 98°C for 20 sec, 62°C for 20 sec, 
72°C for 30 sec) was performed with the Nextera adapter primers P1 (5’-
AATGATACGGCGACCACCGA-3’) and P2 (5’-CAAGCAGAAGACGGCATACGA-3’) to enrich the 
library for tagmented fragments containing the Index 1-Index 2 adapter combination at their ends.  
DNA libraries were prepared in 96-well plates.  Agencourt AMPure XP beads (Beckman Coulter 
Inc., Indianapolis, IN) were used to purify PCR amplicons and to size select ~300bp fragments; 
eight PCR reactions from each column were combined into a single tube and incubated with 
136µl of AMPure XP beads for 5 min at room temperature. Beads were washed thrice with 70% 
ethanol, air-dried for 5 min, and the bound DNA was eluted in 100µl of 10mM Tris-HCl (pH 8.0).  
Eluted DNA from all 96 wells were pooled and quantified using Qubit (ThermoFisher Scientific, 
Waltham, MA) and the Agilent DNA 1000 Kit on a 2200 TapeStation instrument (Agilent 
Technologies, Santa Clara, CA) to determine the molar concentration of the ~300bp fragments. 
The pooled library was then diluted to a concentration of 4nM in 10mM Tris-HCl (pH 8.0) and 
stored at -20˚C until sequencing.  Sequencing was performed using Illumina MiSeq or MiniSeq 
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instruments (Illumina Inc, San Diego, CA).  Libraries containing 96 samples were run using 
Illumina MiSeq Nano Kit v2 300.  Libraries containing 192 samples were run using Illumina MiSeq 
Micro Kit v2 300 or Illumina MiniSeq Mid Output Kit 300 (Illumina Inc., San Diego, CA).  
All reads were trimmed of adapter sequences, and paired-end reads were combined into 
a single file, binned for each sample based on index sequences, and assembled to a subtype-
matched HIV-1 reference genome using the Cutadapt and SPAdes genome assembler utilities (8, 
9).  Contigs that aligned to the HIV-1 reference sequence were then used to generate a new 
sample-specific consensus sequence using reads from triplicate amplifications. Reads were then 
re-aligned to this sample-matched reference to generate a final full-length isolate consensus 
sequence using Geneious 9.0  (10). Each nucleotide position of this consensus sequence was 
inspected for the presence of mixed bases, and isolates that exhibited more than 15% diversity at 
any one position in the alignment were considered to contain more than one variant and removed 
from further analysis.  
 
Particle Env content.  250µl aliquots of viral stocks were depleted of microvesicles using 
magnetic beads coated with anti-CD45 antibody (ThermoFisher Scientific, Waltham, MA). Virions 
were then isolated from the microvesicle-depleted supernatants using the VitalVirus HIV Isolation 
kit (Miltenyi Biotec Inc., San Diego, CA) and lysed to release viral proteins. The amount of 
particle-associated reverse transcriptase activity was determined using a colorimetric Reverse 
Transcriptase Assay (Sigma-Aldrich, St Louis, MO). Particle-associated Env content was 
determined using an in-house quantitative ELISA. 96-well plates were coated with 200ng of 
eCD4-Ig (11) in 100µl of 0.2M sodium carbonate/bicarbonate buffer overnight at 4°C. Wells were 
washed twice with 200µl of PBS containing 0.2% Tween 20 (PBS-T), blocked at room 
temperature for two hours with 200µl of 5% milk in PBS-T, and washed three times with PBS-T. 
100µl of virus lysate was added per well and incubated at 37°C for two hours. After washing wells 
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five times with PBS-T, 100µl of polyclonal human anti-gp120 conjugated to horseradish 
peroxidase (ABL Inc., Rockville, MD) was added for one hour at 37°C. Wells were again washed 
five times with PBS-T, incubated with 100µl o-phenylenediamine dihydrochloride substrate 
(ThermoFisher Scientific, Waltham, MA) at room temperature for 30 minutes, and then 
absorbance was read at 450nm. Env content was calculated using a standard curve of 
recombinant gp120 (10ng to 125pg in 2-fold dilutions), which was then normalized by reverse 
transcriptase activity. Stocks previously characterized by a similar protocol (12), as well as viral 
stocks independently quantified for Env content (13), were used to validate the Env ELISA (r = 
0.82, P < 0.0001). 
 
Analysis of per-particle infectivity. Individual wells of a 96-well plate were seeded with 8.3 x 
103 TZM-bl cells in 100µl of 10% FBS-containing DMEM medium to achieve ~30% confluence. 24 
hours later, cells were infected with 100µl of virus, diluted serially in 10% DMEM with 80µg/ml 
DEAE dextran. 12-15 hours post-infection, the T-1249 fusion inhibitor was added (0.01 mg/ml) to 
prevent multiple rounds of infection. Infections were terminated at 48 hours and cells were lysed 
in 75µl lysis buffer (Promega Life Sciences, Madison, WI). Relative light units (RLU) generated 
per volume of each viral stock were calculated by averaging all virus dilutions in the linear range 
of the assay (1.5x103 - 7x104 RLUs). The infectivity per particle was then calculated as the RLU 
generated per pg of RT activity present in each virus stock. 
 
Replicative capacity and type I IFN resistance. Activated normal donor CD4+ T cells were left 
untreated or cultured in the presence increasing amounts of IFNα2 (0.00074 pg/ml - 5.5 pg/ml) or 
IFNβ (0.000067 pg/ml - 0.44 pg/ml) for 24 hours. Cells were washed, and 1x106 cells were 
infected overnight with an equivalent amount of each virus (1ng RT activity). Supernatants were 
sampled every 48 hours, and cultures were maintained for 7 days while replenishing IFN-
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containing medium. Virus replication was measured for each IFN concentration as the amount of 
p24 produced at day 7 and plotted as the percentage of viral growth in the absence of IFN, which 
was set to 100%. This allowed us to determine the IFNα2 and IFNβ concentrations required to 
inhibit virus replication by 50% (IC50) as well as the residual virus replicative capacity (Vres) in the 
presence of maximal IFNα2 and IFNβ concentrations. The replicative capacity of each virus 
isolate was calculated using p24 antigen levels in untreated cells. Some viruses replicated to 
titers below the limit of detection in the presence of maximal IFNβ concentrations. For these 
viruses, the limit of detection (0.1 ng of p24/ml) was used as the numerator to calculate Vres. 
IFNα2 IC50 values were determined using pooled CD4+ T-cells from 4 donors, while IFNβ IC50 
values were determined using pooled CD4+ T-cells from 3 donors (Fig. 2.2A and B). All viruses 
were tested in duplicate. 
 
Quantification of virus release. CD4+ T-cells were infected as described above. To quantify 
cell-associated p24, cells and supernatant were harvested 7 days post-infection after 
centrifugation at 1,200 rpm for 5 min. Cells were lysed, and cell-free and cell-associated p24 
antigen levels were quantified using the HIV p24 (high sensitivity) AlphaLISA Detection Kit 
(Perkin Elmer Inc., Boston, MA). For each isolate, total p24 production was calculated by adding 
cell-free and cell-associated p24 levels. The percent of released p24 was determined by dividing 
the cell-free amount of p24 by the total amount of p24 as previously described (14, 15). 
 
Phylogenetic analyses. Nucleotide sequences were aligned using CLUSTALW v. 2 (16). 
Regions that could not be unambiguously aligned were removed. Maximum likelihood trees with 
bootstrap support (1,000 replicates) were constructed using PhyML v. 3.1 (17) with evolutionary 
models selected using jModelTest v. 2.1.4 (18, 19), or for larger datasets, RAxML using a 
GTRGAMMA model (20). Transmitted founder viral genomes were inferred as described 
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previously (5). Highlighter plots were generated using the Los Alamos National Laboratory HIV 
Sequence Database Highlighter Tool 
(https://www.hiv.lanl.gov/content/sequence/HIGHLIGHT/highlighter_top.html). The degree of 
phylogenetic association of sequences was quantified by calculating their genealogical sorting 
index (gsi) (21). Maximum likelihood phylogenies were inferred using PhyML (17) and multiple 
bifurcations with intervening zero-length branches were collapsed to polytomies using the di2multi 
method implemented in the ape package (22) of R (23). These phylogram topologies were used 
to calculate the gsi values; p-values were determined using 10,000 replicate permutations (21). 
 
Statistical analyses. For intra-pair comparisons of viral properties, p-values were determined 
using Welch's unequal variances t-test. Analyses were performed in R (23), comparing log10-
transformed values for matched donor and recipient isolates for each transmission pair. Some 
isolates had undetectable p24 values after treatment with IFNβ. Since the unmeasurable range of 
p24 antigen (0 to 0.1 ng/ml) was negligible in comparison to the measurable range (0.1 to 150 
ng/ml), a value of 0.1 ng/ml was used as the numerator for calculating IFNβ Vres values. Principal 
component and receiver operating characteristic analysis (24) were performed using R v3.3.1 
(23). 
 
Bayesian hierarchical regression models of viral properties. Each viral property, was 
modeled using a Bayesian hierarchical model (25), which was based on a linear regression 
estimating the differences between donor plasma and genital secretion isolates, or donor plasma 
and recipient plasma isolates, along with the effects of HIV-1 subtype, and IFNα2 and IFNβ-
selection. Unlike a normal linear regression, this model accounts for (i) nested measurements 
within transmission pairs, (ii) multiple transmissions from a single donor, (iii) heteroscedasticity 
among virus populations, and (iv) censored data where exact measurements were not available 
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but known to be less than a given value. The hierarchical models are based on the assumption 
that observations of viral properties are independent and identically normally distributed with 
mean and variance drawn from common population-level distributions. Estimates of the 
population-level distributions can then be used to infer broader patterns in the data. 
 
 
Data were first transformed as follows: 
 
Variable Transformation 
Env/RT log 
Infectivity log 
Replicative capacity log 
IFNα2 IC50  log 
IFNβ IC50 log 
IFNα2 Vres  logit 
IFNβ Vres  logit 
p24 antigen release  logit 
The observation from each viral isolate 𝑖 was then modeled as a normal distribution  𝑁(𝜇! ,𝜎!!) with mean 𝜇!: 
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and variance 𝜎!!: 
  
  
 
 
where pair !  indicates the pair identity of the 𝑖th observation, donor! is the estimated mean of 
untreated donor plasma viral isolates from pair 𝑗 and 1 () is an indicator function that is 1 if True 
and 0 if False. The various β values are coefficients modeling the change expected for viruses in 
recipients, in donor genital samples, in recipients infected with HIV-1 clade B, and the effects of 
IFNα2 and IFNβ-selection on donor or recipient viruses. For example, a donor plasma virus 𝑖 
from pair 2 would have mean 𝜇! =  donor! and an IFNα2-selected recipient virus from pair 3 
(which happened to be clade B) would have mean:  
 
 For two transmission pairs where one donor (CH742) transmitted viruses to two separate 
recipients (CH378 and CH831), recipient parameters were estimated independently for each 
recipient. 
	
	
105	
Vres measurements were calculated as the amount of p24 released in the presence of 
the highest IFN dose divided by the released p24 without IFN treatment as measured by 
AlphaLISA. The limit of detection for these measurements was 0.1, so concentrations ≤ 0.1 were 
measured as 0.1. To account for this, the probability of these observations was considered to be:  
 
 
 
The coefficients 𝛽 for each pair 𝑗 come from population-level normal hyperpriors: 
 
and coefficients 𝜎 from population-level normal hyperpriors: 
 
 The effect hyperparameters 𝜇!"#$%$"&' , 𝜇!"#$%&', 𝜇!"#$%, 𝜇!"#"$%&'(), 𝜇!"#"$%&'(, 𝜇!"#$%$"&'()%*+ 
and 𝜇!"#$%$"&'("') were all given a flat prior probability. The variance parameters 
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𝜎!"#"$,𝜎!"#$%$"&',𝜎!"#$%&',𝜎!"#$%,𝜎!"#"$%&'(),𝜎!"#"$%&'(, 𝜎!"#$%$"&'()%*+, 𝜎!"#$%$"&'("'), 𝜙!"#"$, 𝜙!"#"$%&'(), 𝜙!"#"$%&'(, 𝜙!"#$%$"&', 𝜙!"#$%&', 𝜃!"#"$, 𝜃!"#"$%&'(), 𝜃!"#"$%&'(, 𝜃!"#$%$"&' and 𝜃!"#$%&' were given a prior 
of Gamma (1,2) reflecting prior knowledge that the standard deviation in these assays was 
unlikely to be greater than several logs. 
Plots and statistics are based on the estimated posterior probabilities of the population-
level effects 𝜇!"#$%$"&' , 𝜇!"#$%&', 𝜇!"#$%, 𝜇!"#"$%&'(), 𝜇!"#"$%&'(, 𝜇!"#$%$"&'()%*+ and 𝜇!"#$%$"&'("'). Markov 
Chain Monte Carlo sampling of the posterior probability distributions of the models was 
implemented in Stan (26) using the R package rstan (23) and run in 50 chains with each having a 
50,000 iteration burn-in and 50,000 iterations of sampling every 25th iteration.  
Biological data and analysis code are archived on Zenodo at: 
DOI: 10.5281/zenodo.21645 
 As an example for why these Bayesian estimates are more conservative than simpler 
analyses, we can look at the estimated change in IFNβ IC50 between untreated donor plasma 
viruses and IFNβ-selected donor plasma viruses (Fig. 2.3). We observed log10(IC50) in both 
untreated and IFNβ-selected viral isolates for 3 donors with averages:   
 
 
 
 
 
The simplest estimate would be to take the average, 1.423, and the standard deviation, 
0.0733, of the three differences and estimate the 95% confidence interval on the mean as:  
Donor Untreated IFNβ-selected Difference 
CH148 -4.269 -2.831 1.438 
CH492 -4.203 -2.717 1.487 
CH596 -4.162 -2.820 1.343 
	
	
107	
 
Or equivalently an estimate that IFNβ-selected donor viruses have an IC50 26.5-fold (95% 
confidence interval: 21.9–32.0-fold) higher than untreated isolates. In contrast, the Bayesian 
model yielded estimates of 20.7-fold (95% credible interval: 11.0–36.2-fold) higher IC50 values.  
Thus, the Bayesian model represents a more conservative approach that yields wider intervals in 
its estimation due to the incorporation of uncertainty in our estimates of untreated and IFNβ-
selected IC50 values for each donor. 
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Table S2.1. Generation of limiting-dilution isolates from eight epidemiologically linked transmission pairs 
Subject Transmission Partner 
Risk
Factor  Subtype Country Gender VL 
Fiebig 
Stage* 
Number 
of TF 
Viruses 
Sample Date UT IFNα2selected 
IFNβ 
selected Days
‡
Accession Codes 
Isolate Sequences§ SGA Sequences¶ 
CH0742 Donor MSM B USA M 112,531 PL 09/10/08 15 3 0 KY112461-KY112478 KY112494-KY112521 
na SEM 08/27/08 1 0 0 KY112480 
na SEM 09/10/08 11 0 0 KY112481-KY112491 
na SEM 10/29/08 1 0 0 KY112492 
na SEM 12/10/08 1 0 0 KY112493 
na SEM 03/18/09 0 0 0 
CH0378 Recipient 1 M 265,936 5 2 PL 08/05/08 17 7 0 36 KY112136-KY112159 KY112160-KY112189 
CH0831 Recipient 2 M 261,752 3 1 PL 11/14/08 8 4 4 65# KY112522-KY112537 KY112538-KY112576 
CH0148 Donor MSM B USA M 246,017 PL 12/19/06 12 3 4 KY112056-KY112074 KY111920-KY111946 
CH0040 Recipient M 298,026 1-2 1† PL 07/27/06 5 2 0 145 KY112190-KY112196 FJ495827-FJ495838 
CH0728 Donor MTF B USA M 23,965 PL 07/28/08 14 1 0 KY112429-KY112445 KY111983-KY111986 KY112446-KY112460 
na SEM 07/27/08 0 0 0 
na SEM 08/27/08 0 0 0 
na SEM 11/04/09 0 0 0 
na SEM 05/13/10 0 0 0 
CH0302 Recipient F 16,218 5 1 PL 04/16/08 7 3 0 103 KY112127-KY112135 KY111947-KY111964,KY364886  
CH0492 Donor FTM C MWI F 472,129 PL 03/11/08 13 19 14 KY112276-KY112321 KY112322-KY112359 
22,753 CVL 02/06/08 17 0 0 KY112259-KY112275 
7,582 CVL 02/21/08 0 0 0 
na CVL 03/11/08 0 0 0 
 
14,596 CVL 04/28/08 0 0 0 
CH0427 Recipient M 1,644,231 1-2 1 PL 01/23/08 10 10 1 47 KY112197-KY112217 KY112218-KY112250 
CH0596 Donor FTM C MWI F 250,981 PL 04/03/08 12 10 6 KY112362-KY112389 KY112390-KY112428 
na CVL 04/03/08 2 0 0 KY112360-KY112361 
 
na CVL 04/17/08 0 0 0 
CH0455 Recipient M 502,665 3 1 PL 01/29/08 5 3 0 65 KY112251-KY112258 KY111965-KY111982 
CH0212 Donor FTM C ZAF F 111,427 PL 08/01/07 11 1 0 KY112082-KY112093 KY112094-KY112126 
CH0162 Recipient M 18,260 3 1† PL 07/13/07 5 2 0 19 KY112075-KY112081 JX972986-JX972998 
CH1064 Donor FTM C MWI F 323,674 PL 04/08/09 18 10 0 KY111987-KY112014 KY112015-KY112055 
bld CVL 02/11/09 0 0 0 
bld CVL 02/25/09 0 0 0 
na CVL 04/08/09 0 0 0 
990 CVL 07/07/09 0 0 0 
CH0848 Recipient M 361,254 4 1 PL 07/29/08 4 4 0 265 KY112577-KY112584 KX216883-KX216893
KX216895 
MSM, men who have sex with men; MTF, male to female; FTM female to male; USA, United States; MWI, Malawi; ZAF, South Africa; M, male; F, female; PL, plasma; SEM, semen; CVL, 
cervicovaginal lavage; VL, viral load (RNA copies per milliliter of plasma); na, data not available; bld, below limit of detection; UT, untreated. Viral load determination, Fiebig staging, and 
limiting dilution virus isolation were performed on the same sample from the indicated time point. 
*defined as previously described (2).
†infectious molecular clone (IMC) available
‡number of days between recipient and first available donor samples.
#in contrast to all other recipients, CH831 was sampled 64 days after donor CH742.
§Isolate sequences represent near-complete viral genomes (8,750-9,208 bp).
¶SGA sequences span rev-vpu-env-nef gene regions (2,922-2,973 bp for KY112446-KY112460) or 3’ half genomes (4,112-4,936 bp).
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Donor IFN-Selected Untreated 
CH1064 0.175 0 
CH148 0.143 0 
CH492 0.136 0.112 
CH596 0.124 0.094 
CH742 0.095 0 
To assess the extent of segregation of plasma isolates generated in IFN-selected and untreated CD4+ T cells, we constructed maximum 
likelihood trees of full-length isolate sequences and calculated their genealogical sorting index (gsi) (21) using the genealogical Sorting R 
package (http://molecularevolution.org/software/phylogenetics/gsi/download).  Gsi indices range between 0 (no segregation) and 1 (complete 
monophyly). Statistical significance was assessed by randomly permuting character states across the tips of the tree 10,000 times. None of the 
values was significant, indicating complete interspersion (p values were corrected for multiple tests). 
Table S2.2A.  Genealogical sorting index analysis of sequences from uncultured plasma and limiting dilution 
isolates Donor Plasma SGA Plasma Isolates 
CH1064 0.039 0.120 
CH148 0.059 0.092 
CH212 0.142 0.421** 
CH492 0.119 0.100 
CH596 0.065 0.110 
CH728§ 0.346* 0.136 
CH742 0.090 0.224 
To assess to what extent viral isolates were representative of the virus present in the plasma of the chronically infected donors, we constructed 
maximum likelihood phylogenetic trees from 3’ half genome or env gene§ sequences and used these to assess the degree of segregation 
between single genome amplification derived plasma (Plasma SGA) and limiting dilution derived isolate (Plasma Isolates) sequences by 
determining their genealogical sorting index (gsi) (21). Gsi indices range between 0 (no segregation) and 1 (complete monophyly) and were 
calculated using the genealogical Sorting R package (http://molecularevolution.org/software/phylogenetics/gsi/download). Two gsi values, 
which were significantly higher than expected from random segregation, are indicated (* p<0.05; ** p < 0.01).  For CH212, available plasma 
isolates represented only two of three diverse viral lineages present in this donor’s quasispecies, indicating insufficient sampling (Fig. S3F). For 
CH728, the high gsi value was due to two clusters of near identical isolate sequences, indicating repeat culture of the same virus (Fig. S3C). 
Collapsing one of these clusters to a single sequence reduced the Plasma SGA and Plasma Isolate gsi values to non-significant values (0.3 
and 0.116, respectively). For all other donors, limiting dilution isolates were fully representative of the viral diversity present in the plasma. 
Statistical significance was assessed by randomly permuting character states across the tips of the tree 10,000 times (p values were corrected 
for multiple tests). 
Table S2.2B. Genealogical sorting index analysis of sequences from plasma and genital secretion isolates 
Donor Genital Secretion Isolates Plasma Isolates 
CH492 0.142 0.225 
CH742 0.236 0.333* 
To assess the extent of segregation of plasma and CVL isolates for donor CH492, and plasma and semen isolates for donor CH742, we 
constructed maximum likelihood trees of full-length plasma and genital secretion isolate sequences, and used these to calculate the 
genealogical sorting index (http://molecularevolution.org/software/phylogenetics/gsi/download) (21). Gsi indices range between 0 (no 
segregation) and 1 (complete monophyly), and values that were significantly higher than expected from random segregation are indicated (* 
p<0.05).  For CH742, the high gsi value was due to a pair of nearly identical semen isolate sequences, indicating repeat culture of the same 
virus (Fig. S3A). Collapsing this cluster to a single sequence reduced the genital secretion and plasma isolates gsi values to non-significant 
values (0.229 and 0.187, respectively). Statistical significance was assessed by randomly permuting character states across the tips of the tree 
10,000 times. Non-significant values indicate the absence of compartmentalization (p values were corrected for multiple tests). 
Table S2.2C. Genealogical sorting index analysis of sequences from IFN-selected and untreated plasma isolates 
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Fig. S2.1. Confirmation of epidemiological linkage of transmission pairs. 3’ half genome 
sequences were generated by single genome amplification (SGA) of viral RNA from the plasma 
of respective donors and recipients.  Nucleotide sequences of partial tat, partial rev, vpu, env and 
partial nef genes were aligned using CLUSTALW v. 2 (16), with ambiguous regions removed (the 
2,654 bp alignment spans HXB2 coordinates 5,984-8,866). A maximum likelihood tree with 
bootstrap support (1,000 replicates) was constructed using RAxML v. 8.0.22 (20) with a 
GTRGAMMA evolutionary model. Sequences from donors and acutely infected recipients are 
indicated by green and red rectangles, respectively, with brackets denoting individual 
transmission pairs. Donor CH742 transmitted to two recipients (Fig. S2.2), one of whom (CH378) 
acquired two transmitted founder viruses (v1 and v2). Also shown for CH378 are sequences that 
are recombinant between v1 and v2 (red rectangles with black circles). Subtype B reference 
sequences (labeled by accession code) included HXB2 (K03455), BK132 (AY173951), 1058 
(AY331295) and 671_00T36 (AY423387), while subtype C reference sequences included 
ETH2220 (U46016), BR025 (U52935), 95IN21068 (AF067155) and 04ZASK146 (AY772699). 
Asterisks indicate nodes with ≥ 95% bootstrap support (the scale bar represents 0.05 
substitutions per site). 
 
 
	
	
116	
 
 
 
A
B
96194913 5913 6913 7913 8913
HXB2 alignment position 
4906 5906 6906 7906 8906 9622
HXB2 alignment position 
1 bp
CH378 v1.TF
CH378_SGA.2C10
CH378_SGA.1D1
CH378_SGA.2H11
CH378_SGA.1B2
CH378_SGA.1F8
CH378_SGA.2F4
CH378_SGA.2F11
CH378_SGA.1F5
CH378_SGA.2D5
CH378_SGA.1C4
CH378_SGA.2H5
CH378_SGA.1G2
CH378_SGA.1A3
CH378_SGA.2D12
CH378_SGA.1H4
CH378_SGA.2C4
CH378_SGA.2E11
CH378_SGA.1D6
CH378_SGA.1A4
CH378_SGA.2G8
CH378_SGA.1D2
CH378_SGA.1F4
CH378_SGA.1H9
CH378_SGA.2H7
CH378_SGA.2H9
CH378_SGA.2H10
CH378_SGA.1G11
CH378_SGA.2F3
CH378_SGA.2B11
CH378 v2.TF
CH378_SGA.2E6
A C G T
1 bp
CH831.TF
CH831_SGA.43S83
CH831_SGA.19S59
CH831_SGA.37S77
CH831_SGA.40S80
CH831_SGA.1S41
CH831_SGA.22S62
CH831_SGA.9S49
CH831_SGA.8S48
CH831_SGA.4S44
CH831_SGA.47S87
CH831_SGA.36S76
CH831_SGA.35S75
CH831_SGA.29S69
CH831_SGA.12S52
CH831_SGA.7S47
CH831_SGA.20S60
CH831_SGA.41S81
CH831_SGA.2S42
CH831_SGA.34S74
CH831_SGA.11S51
CH831_SGA.14S54
CH831_SGA.3S43
CH831_SGA.44S84
CH831_SGA.15S55
CH831_SGA.39S79
CH831_SGA.10S50
CH831_SGA.48S88
CH831_SGA.25S65
CH831_SGA.46S86
CH831_SGA.52S92
CH831_SGA.56S96
CH831_SGA.17S57
CH831_SGA.26S66
CH831_SGA.42S82
CH831_SGA.45S85
CH831_SGA.53S93
CH831_SGA.28S68
CH831_SGA.38S78
CH831_SGA.23S63
A C G T
R
R
R
R
R
	
	
117	
 
 
 
D
E
C A C G T
A C G T
A C G T
1 bp
CH302_SGA.5.08
CH302_SGA.5.13
CH302_SGA.5.04
CH302_SGA.5.05
CH302_SGA.5.17
CH302_SGA.5.21
CH302_SGA.5.06
CH302_SGA.5.14
CH302_SGA.5.15
CH302_SGA.5.23
CH302_SGA.5.24
CH302_SGA.5.16
CH302_SGA.5.19
CH302_SGA.5.20
CH302_SGA.5.01
CH302_SGA.5.12
CH302_SGA.5.09
CH302_SGA.5.18
CH302.TF
HXB2 alignment position 
HXB2 alignment position 
HXB2 alignment position 
4924 5924 6924 7924 8924 9603
1 bp
CH427.TF
CH427_SGA.600.30
CH427_SGA.600.31
CH427_SGA.600.32
CH427_SGA.600.33
CH427_SGA.600.35
CH427_SGA.600.36
CH427_SGA.600.3
CH427_SGA.600.12
CH427_SGA.600.16
CH427_SGA.600.19
CH427_SGA.600.25
CH427_SGA.600.27
CH427_SGA.600.2
CH427_SGA.600.8
CH427_SGA.600.37
CH427_SGA.600.18
CH427_SGA.600.9
CH427_SGA.600.4
CH427_SGA.600.14
CH427_SGA.600.11
CH427_SGA.600.20
CH427_SGA.600.29
CH427_SGA.600.15
CH427_SGA.600.7
CH427_SGA.600.26
CH427_SGA.600.22
CH427_SGA.600.6
CH427_SGA.600.39
CH427_SGA.600.24
CH427_SGA.600.1
CH427_SGA.600.13
CH427_SGA.600.10
59324932 6932 7932 8932 9577
4924 5924 6924 7924 8924 9603
1 bp
CH455_SGA.5.19
CH455_SGA.5.09
CH455_SGA.5.01
CH455_SGA.5.11
CH455.TF
CH455_SGA.5.25
CH455_SGA.5.29
CH455_SGA.5.30
CH455_SGA.5.31
CH455_SGA.5.06
CH455_SGA.5.05
CH455_SGA.5.07
CH455_SGA.5.14
CH455_SGA.5.32
CH455_SGA.5.08
CH455_SGA.5.12
CH455_SGA.5.28
CH455_SGA.5.26
CH455_SGA.5.15
	
	
118	
 
Fig. S2.2. Transmitted founder sequence inference and enumeration. Neighbor-joining 
phylogenetic trees (left) and highlighter plots (right) were generated for SGA derived 3’ half 
genome sequences using the Los Alamos National Laboratory HIV Sequence Database 
Highlighter Tool (5). In the phylogenetic trees, the inferred transmitted founder (TF) sequence is 
shown at the top. The scale bar represents one base pair difference. In the highlighter plots, the 
TF sequence is used as the reference and indicated by a thick line. Thinner lines below 
correspond to sequences shown in the phylogenetic tree to the left. Tick marks indicate 
nucleotide differences from the TF sequence (green, A; blue, C; G orange; T, red).  (A) 
Sequences from the acute recipient CH378 (4,774 bp) span HXB2 coordinates 4,913-9,619. For 
this recipient, two TF variants (v1 and v2) were identified. The former was used as a reference for 
the highlighter plot, but both variants are shown as thick lines. A bold-faced R preceding the 
sequence name indicates recombinants between these two variants. (B) Sequences from 
recipient CH831 (4,783 bp) span HXB2 coordinates 4906-9622. (C) Sequences from recipient 
CH302 (4,757 bp) span HXB2 coordinates 4924-9603. (D) Sequences from recipient CH427 
(4,674 bp) span HXB2 coordinates 4932-9577. (E) Sequences from recipient CH455 (4,696 bp) 
span HXB2 coordinates 4924-9603. TF sequence inference and enumeration of the remaining 
three recipients (CH040, CH162, and CH848) have been published (4, 12, 27). 
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Fig. S2.3. Limiting dilution-derived isolates are representative of the viral quasispecies 
present in vivo.  The phylogenetic relationships of limiting dilution-derived isolate and SGA-
derived plasma viral sequences are shown for all transmission pairs. Maximum likelihood trees 
with bootstrap support (1,000 replicates) were constructed using PhyML v. 3.1 (17) with 
evolutionary models selected using jModelTest v. 2.1.4 (19). For transmitting donors, plasma 
isolates (labeled PL, followed by the date and the isolate number), genital secretion isolates 
(labeled SE for semen and CV for cervicovaginal lavage, followed by the date and isolate 
number), and plasma vRNA derived SGA sequences (labeled SGA, followed by the amplicon 
number) are indicated in green, purple and blue, respectively. For acutely infected recipients, 
plasma isolate and SGA sequences (labeled like donor isolates) are shown in red and brown, 
respectively. Nodes with ≥ 75% bootstrap support are indicated (the scale bars represent 0.01 
substitutions per site). (A) 3’ half genome sequences from donor CH742 and his two recipients 
CH831 and CH378 denoted by brackets (4,358 bp). CH378 acquired two TF viruses, termed v1 
and v2 (recombinants of these are labeled R). (B) 3’ half genome sequences from donor CH148 
and recipient CH040 (4,481 bp). SGA sequences for CH040 are available under GenBank 
accession codes: FJ495827 - FJ495838. (C) tat/rev, env and nef sequences from donor CH728 
and recipient CH302 (2,829 bp). (D) 3’ half genome sequences from donor CH492 and recipient 
CH427 (4,539 bp). (E) 3’ half genome sequences from donor CH596 and recipient CH455 (4,501 
bp). (F) 3’ half genome sequences from donor CH212 and recipient CH162 (4,463 bp). SGA 
sequences for CH162 are available under GenBank accession codes: JX972986 - JX972998. (G) 
3’ half genome sequences from donor CH1064 and recipient CH848 (4,550 bp). SGA sequences 
for CH848 are available under GenBank accession codes: KX216883 - KX216893 and 
KX216895. 
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Fig. S2.4. Env content, particle infectivity and replicative capacity of limiting dilution-
derived isolates from matched donor and recipient pairs. (A) Env content (gp120:RT mass 
ratio), (B) particle infectivity (relative light units [RLU] in the TZM-bl assay per picogram of RT), 
and (C) replicative capacity (ng of p24 per ml of CD4 T cell culture supernatant at day 7 post 
infection) are shown for each limiting dilution-derived isolate of each transmission pair. Each dot 
represents an individual isolate derived from donor plasma (PL, green), donor genital secretions 
(CVL or SEM, purple), or recipient plasma (PL, red). Black lines denote the geometric mean, and 
fold changes are listed above groups when significant (P < 0.05).  
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Fig. S2.5. IFN resistance of limiting dilution-derived isolates from matched donor and 
recipient pairs. Donor and recipient isolates were tested for their sensitivity to inhibition by type 1 
IFNs. (A) Half-maximal inhibitory concentrations (IC50) for IFNα2 (pg/ml); (B) residual viral 
replication (Vres) at the highest (5.5 pg/ml) IFNα2 dose (Vres); (C) Half-maximal inhibitory 
concentrations (IC50) for IFNβ (pg/ml); (D) residual viral replication (Vres) at the highest (0.44 pg) 
IFNβ dose. Each dot represents an individual isolate derived from donor plasma (PL, green), 
donor genital secretions (CVL or SEM, purple), or recipient plasma (PL, red). Black lines denote 
the geometric mean, and fold changes are listed above groups when significant (P < 0.05). 
Orange dots indicating IFNα2 and IFNβ IC50 and Vres values for two available (CH040 and 
CH162) TF virus infectious molecular clones (4, 12) are shown for control. 
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Fig. S2.6. Residual viral replication (Vres) of untreated and IFN-selected isolates from 
matched donor and recipient pairs. (A, C) Donor and recipient isolates were tested for their 
ability to replicate in CD4+ T cells in the presence of maximal doses of IFNα2 (A) and IFNβ (C), 
expressed as the percentage of viral growth retained relative to growth in the absence of IFN. 
Viruses are colored by transmission pair and include untreated as well as IFNα2-selected and 
IFNβ-selected isolates from both donors and recipients. (B, D) A hierarchical Bayesian regression 
model was used to estimate the population-wide fold change in the odds of retaining replication in 
the presence of maximal (non-toxic) doses of IFNα2 (B) or IFNβ (D), when comparing untreated 
and IFNα2-selected donor plasma isolates (blue), untreated and IFNβ-selected donor plasma 
isolates (green), untreated donor plasma and genital secretion isolates (purple), untreated donor 
and recipient plasma isolates (red), untreated and IFNα2-selected recipient plasma isolates 
(grey) and untreated and IFNβ-selected recipient plasma isolates (yellow). The dashed vertical 
line marks a fold change of 1, indicating no effect. The estimated posterior probability distribution 
for each parameter is shown along with a table summarizing the expected fold change, and the 
probability that the effect is less than 1. 
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Fig. S2.7. Phylogenetic relationships of IFN-selected and unselected isolates from 
matched donor and recipient pairs. Nucleotide sequences were aligned using CLUSTALW v. 2 
(16), with ambiguous regions removed. Maximum likelihood trees with bootstrap support (1,000 
replicates) were constructed using PhyML v. 3.1 (17) with evolutionary models selected using 
jModelTest v. 2.1.4 (19). Donor plasma isolate sequences (labeled PL, followed by the date and 
the isolate number) and genital tract isolate sequences (labeled SE for semen and CV for 
cervicovaginal lavage, followed by the date and isolate number) are shown in green and purple, 
respectively, while recipient plasma isolate sequences are shown in red (labeled PL, followed by 
the date and the isolate number). Isolates obtained in CD4+ T cells pretreated with IFNα2 (A2) or 
IFNβ (BE) are highlighted by asterisks and triangles, respectively. Bootstrap values ≥ 75% are 
shown (scale bars represent 0.01 substitutions per site). (A) Phylogenetic tree of near complete 
isolate sequences (8,812 bp) from donor CH742 and recipients CH831 and CH378 (denoted by 
brackets). CH378 was infected by two TF viruses (v1 and v2; recombinants of v1 and v2 are 
indicated with an “R”). (B) Phylogenetic tree of near complete isolate sequences (8,737 bp) from 
donor CH148 and recipient CH040; (C) Phylogenetic tree of near complete isolate sequences 
(8,872 bp) from donor CH728 and recipient CH302; (D) Phylogenetic tree of near complete 
isolate sequences (8,582 bp) from donor CH492 and recipient CH427; (E) Phylogenetic tree of 
near complete isolate sequences (8,674 bp) from donor CH596 and recipient CH455; (F) 
Phylogenetic tree of near complete isolate sequences (8,795 bp) from donor CH212 and recipient 
CH162; (G) Phylogenetic tree of near complete isolate sequences (8,861 bp) from donor CH1064 
and recipient CH848. Arrows indicate examples of isolates with identical vpu sequences that 
differed in their p24 release capacity.  
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Section 3.1- Abstract  
 
 
HIV-1 groups M, N, O and P are the result of independent zoonotic transmissions of SIVs 
infecting great apes in Africa. Among these, only Vpu proteins of pandemic HIV-1 group M strains 
evolved potent activity against the restriction factor tetherin, which inhibits virus release from 
infected cells. Thus, effective Vpu-mediated tetherin antagonism may have been a prerequisite 
for the global spread of HIV-1. To determine whether this particular function enhances primary 
HIV-1 replication and interferon resistance, we introduced mutations into the vpu gene of HIV-1 
group M and N strains to specifically disrupt their ability to antagonize tetherin, but not other Vpu 
functions, such as degradation of CD4, down-modulation of CD1d and NTB-A, and suppression 
of NF-kB activity. Lack of particular human-specific adaptations reduced the ability of HIV-1 group 
M Vpu proteins to enhance virus production and release from primary CD4+ T cells at high levels 
of type I IFN from about 5-fold to 2-fold. Interestingly, transmitted founder HIV-1 strains exhibited 
higher virion release capacity than chronic control HIV-1 strains irrespective of Vpu function, and 
group M viruses produced higher levels of cell-free virions than an N group HIV-1 strain. Thus, 
efficient virus release from infected cells seems to play an important role in the spread of HIV-1 in 
the human population and requires a fully functional Vpu protein that counteracts human tetherin.    
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Section 3.2 – Importance  
 
 Understanding which human-specific adaptations allowed HIV-1 to cause the AIDS pandemic is 
of great importance. One feature that distinguishes pandemic HIV-1 group M strains from non-
pandemic or rare group O, N and P viruses is the acquisition of mutations in the accessory Vpu 
protein that confer potent activity against human tetherin.  Adaptation was required because 
human tetherin has a deletion that renders it resistant to the Nef protein used by the SIV 
precursor of HIV-1 to antagonize this antiviral factor. It has been suggested that these 
adaptations in Vpu were critical for the effective spread of HIV-1 M strains, but direct evidence 
has been lacking. Here, we show that these changes in Vpu significantly enhance virus 
replication and release in human CD4+ T cells, particularly in the presence of IFN, thus 
supporting an important role in the spread of pandemic HIV-1.   
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SECTION 3.3 – Introduction 
 
Pandemic HIV-1 emerged following the transmission of a simian immunodeficiency virus (SIV) 
from chimpanzees (cpz) to humans early in the 20th century (1). Since then, this major (M) group 
of HIV-1 has infected more than 70 million people and caused more than 30 million deaths. In 
contrast, HIV-1 groups O, N and P, which also resulted from zoonotic transmissions of 
chimpanzee (N) and gorilla (O, P) SIVs, have spread far less efficiently in the human population. 
Group O viruses have been found in about 100,000 individuals in Cameroon and surrounding 
countries (2), while HIV-1 groups N and P viruses are rare and have only been detected in a 
handful of individuals (3, 4).  
 One possible reason for why only HIV-1 group M became pandemic is the acquisition of 
potent anti-tetherin activity by its Vpu protein (5). Tetherin is an antiviral restriction factor that 
inhibits virus release by tethering nascent virus particles to the surface of infected cells (6, 7). 
Most primate lentiviruses including SIVcpz and SIVgor use their Nef protein to antagonize this 
antiviral factor (5, 8, 9). A deletion in the cytoplasmic domain of human tetherin, however, confers 
resistance to SIV Nefs and thus represents a significant barrier for successful zoonotic 
transmission (10, 11). Pandemic group M and (to a much lesser extent) rare group N strains 
acquired Vpu-mediated anti-tetherin activity (5, 12), while HIV-1 group O strains evolved the 
ability to counteract human tetherin by adapting their Nef protein to target a region adjacent to the 
deletion (13). However, neither of the two known group P viruses acquired significant anti-human 
tetherin activity (14, 15). 
 It has been shown that specific amino acid residues in the transmembrane domain (TMD) 
allow HIV-1 group M Vpus to interact directly with the TMD of tetherin and to counteract this 
restriction factor (16-18). In contrast, other Vpu functions are conserved between HIV-1 and its 
simian precursors. For example, SIVcpz and SIVgor Vpus are active in degrading human CD4 (5) 
and in suppressing the transcription factor NF-kB and interferon induction in human cells (19). 
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Furthermore, SIVcpz Vpu proteins downregulate cell surface expression of human NTB-A and 
CD1d (12), which suppress NK cell-mediated lysis of virally infected cells (20) and antigen 
presentation by virally infected dendritic cells, respectively (21). Complete abrogation of Vpu 
impairs HIV-1 replication in primary CD4+ T cells and humanized mice, and renders the virus 
hypersensitive to IFN-α inhibition (22-24). However, it remains unknown how much the more 
recently acquired Vpu-mediated anti-tetherin activity contributes to replication fitness and IFN 
resistance of HIV-1 group M. To address this, we introduced mutations in the TMD of the Vpu 
proteins of six group M infectious molecular clones (IMCs) that specifically abrogated their ability 
to antagonize human tetherin. We show that these changes significantly decrease HIV-1 
replication and increase IFN sensitivity in primary human CD4+ T cells. Thus, human-specific 
adaptation of SIVcpz Vpu was likely required to gain maximal replication fitness of group M 
viruses in the new host and facilitate the successful colonization of humans.  
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SECTION 3.4 – Results 
 
Generation of HIV-1 Vpu mutants that are selectively impaired in tetherin antagonism. 
Efficient counteraction of human tetherin by Vpu distinguishes HIV-1 group M strains from other 
group O, N and P strains (5). To examine the effect of Vpu-mediated tetherin antagonism on HIV-
1 replication and IFN sensitivity in human CD4+ T cells, we generated a panel of infectious 
molecular clones (IMCs) that lacked this specific Vpu function. We achieved this by mutating two 
alanines in the TMD of Vpu, which have previously been shown to be critical for antagonism of 
human tetherin (16-18), to leucines (Fig. 3.1A). These mutations were introduced into two (CCR5-
tropic) transmitted founder (TF) (CH058-TF, CH077-TF) and two chronic control (CC) viruses 
(STCO-CC, CH167-CC) (25). The T-cell line adapted (CXCR4-tropic) NL4-3 clone served as a 
control. All IMCs represented clade B viruses, except for CH167-CC, which is a clade C strain 
(Table 1). For comparison, we also generated a mutant of the group N HIV-1 clone DJO0131 (26) 
to determine whether the modest gain of anti-tetherin activity by this viral lineage (5, 12) is 
sufficient to promote virus replication and release in primary CD4+ T cells.   
 To verify that the introduced mutations abrogated Vpu`s ability to counteract human tetherin, 
we cotransfected HEK293T cells with vectors expressing wild-type (wt) or TMD mutant (Tmut) 
Vpu proteins and eGFP (or eGFP alone for control) together with a construct expressing human 
tetherin. The TMD mutations did not affect Vpu expression levels (Fig. S3.1A), but significantly 
impaired the ability of all HIV-1 M Vpus to reduce tetherin cell surface expression (Fig. 3.1B, 
S3.1B). In agreement with published data (12), the DJO0131 N-Vpu was poorly expressed (Fig. 
S3.1A) and had only a modest effect on tetherin, which was entirely abolished by the TMD 
mutations (Fig. 3.1B, S3.1B). To further examine the effect of these TMD mutations, we analyzed 
the efficiency of virus release from HEK293T cells cotransfected with vpu-defective HIV-1 NL4-3 
together with constructs expressing wt or TMD-mutated Vpu proteins or eGFP only, as well as 
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plasmids expressing human tetherin at different doses. The results showed that the TMD 
mutations completely disrupted the ability of Vpu to enhance virus release (Fig. 1C). Notably, 
HIV-1 M subtype C CH167-CC Vpu antagonized tetherin more efficiently than subtype B and 
group N Vpus (Fig. 3.1C). 
 To determine the specificity of the TMD mutations for the anti-tetherin activity of Vpu, we 
transfected HEK293T cells with vectors co-expressing Vpu and eGFP together with constructs 
expressing CD4, NTB-A or CD1d. All HIV-1 M Vpus strongly reduced cell surface expression of 
CD4, while the group N Vpu had little effect (Fig. S3.1B, S3.1C). Although only Vpus from the two 
CC HIV-1 M strains STCO-CC and CH167-CC significantly reduced NTB-A and CD1d cell 
surface expression (Fig. S3.1D, S3.1E), the effect of Vpu on these receptors was not significantly 
impaired by the TMD mutations. HIV-1 M Vpus also suppressed antiviral gene expression and 
immune activation by inhibiting NF-κB activation (19, 27). Cotransfection of HEK293T cells with 
vectors coexpressing Vpu and eGFP together with an NF-κB-dependent firefly luciferase reporter 
construct and a constitutively active mutant of IKKβ showed that the CH058-TF, CH077-TF and 
STCO-CC Vpus suppressed IKKβ-mediated NF-κB activation by ∼80%, whereas the NL4-3 Vpu 
achieved ~40% inhibition and the HIV-1 N Vpu was inactive (Fig. S2A). Thus, in agreement with 
previous data (19, 28), primary HIV-1 M Vpus inhibited NF-κB more efficiently than the NL4-3 or 
group N Vpu proteins. It has been reported that Vpu may suppress NF-κB activation by at least 
two different mechanisms: antagonism of tetherin (27) and stabilization of IκB and prevention of 
nuclear translocation of p65 (19). Thus, we also analyzed whether the TMD mutations affect the 
ability of Vpu to inhibit tetherin-mediated NF-κB stimulation. Consistent with previous data (27), 
tetherin expression induced NF-κB activation in a dose-dependent manner (Fig. S3.2B). 
However, wt and Tmut Vpu proteins suppressed tetherin-mediated NF-κB activation with similar 
potencies (Fig. S3.2B). This result is in agreement with our previous finding that primate lentiviral 
Vpu proteins efficiently prevent NF-κB activation independent of their anti-tetherin activity (19).  
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 To determine the effect of the TMD mutations on the ability of Vpu to reduce tetherin and CD4 
surface expression levels in primary human cells, PHA-stimulated peripheral blood mononuclear 
cells (PBMCs) were infected with the six sets of HIV-1 infectious molecular clones (IMCs) 
containing wt, TMD mutated or defective vpu genes. The latter contained either a 120 bp deletion 
(NL4-3) or two premature stop codons at positions two and three of the reading frame (all other 
IMCs). Three days later, the cells were stained for surface tetherin and CD4, permeabilized, and 
stained for intracellular p24 expression. On average, wt group M Vpus reduced the surface levels 
of tetherin by ~50%, while HIV-1 N Vpu achieved 34% (Fig. 3.2). Since no specific antibodies are 
available, we could not determine whether the modest activity of the N-Vpu was the result of poor 
activity or low expression levels. The two Ala to Leu substitutions in the TMD domain of Vpu 
generally disrupted tetherin downmodulation in HIV-1-infected primary cells (Fig. 3.2). In contrast, 
all 18 HIV-1 IMCs efficiently reduced CD4 cell surface expression, irrespective of the Vpu allele 
(Fig. S3.3). This is because these proviral HIV-1 constructs express functional Env and Nef 
proteins and particularly the latter is highly effective in down-modulating CD4 in HIV-1-infected T 
cells (29). 
 
Tetherin antagonism is critical for effective HIV-1 production in CD4+ T cells. CD4+ T cells 
are the first productively infected cell type detected in primary HIV-1 infection (30) and TF HIV-1 
strains, which establish de novo clinical infection, are less sensitive to inhibition by type I 
interferon (IFN) than chronic control HIV-1 (31, 32). To determine the role of Vpu-mediated 
tetherin antagonism in virus production and sensitivity to IFN, we infected activated CD4+ T cells 
with equivalent amounts of virus in the presence and absence of IFNαa and determined the 
levels of p24 antigen production in culture supernatants on day 7 post-infection. Because of their 
importance in HIV-1 transmission, we focused on the CH058-TF and CH077-TF viruses and used 
the NL4-3 and chronic CH167-CC IMCs as controls. 
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 In agreement with published data (31, 32), the CH058-TF and CH077-TF HIV-1 IMCs 
produced substantially higher levels of cell-free virus than the chronic CH167-CC or the T-cell line 
adapted NL4-3 construct in the presence, but not in the absence, of IFNαa (Fig. 3.3A). IFNαa 
treatment reduced cell-free p24 yield of wt TF HIV-1 IMCs by ~9-fold. This reduction was 
significantly lower than that observed for NL4-3 (58.2-fold) and the CC CH167-CC IMC (44.1-fold) 
(Fig. 3.3B). Point mutations in the TM domain of Vpu increased IFN sensitivity to a similar extent 
(~3.1-fold) as the complete lack of Vpu (~3.5-fold) (Fig. 3.3B). In the absence of IFNαa, wt 
CH058-TF and CH077-TF Vpus enhanced p24 production by 85% and 189%, whereas the 
corresponding Tmut Vpus achieved only 38% and 121% (Fig. 3.3C). The ability of Vpu to 
enhance cell-free p24 levels was more pronounced in the presence of IFNαa: wt CH058-TF, 
CH077-TF and NL4-3 Vpu proteins increased cell-free p24 antigen yield about 5-fold (Fig. 3.3C). 
In agreement with its potent anti-tetherin activity in transient transfection assays (Fig. 3.1C), the 
CH167-CC Vpu achieved a 9-fold enhancement (Fig. 3.3C), although the corresponding IMC 
produced only low levels of cell-free virus (Fig. 3.3A). Tmut Vpus increased the levels of p24 
antigen in the supernatants of IFNαa CD4+ T cell cultures only marginally compared to HIV-1 
IMCs lacking Vpu function entirely (Fig. 3.3C). Our finding that wt Vpu proteins enhanced the 
levels of cell-free HIV-1 TF viruses in the presence of IFNa substantially more efficiently than 
Tmut Vpus is consistent with a relevant role of tetherin antagonism for viral spread in vivo. 
 
IFNαa treatment impairs release of vpu mutant but not wt HIV-1 strains. To assess the 
effects of the TMD mutations on total virus production and the efficiency of virion release, we 
determined the levels of cell-associated and total p24 antigen in the HIV-1-infected cultures (Fig. 
S3.4A, S3.4B). Total p24 was determined as the sum of both cell-free and cell-associated p24. 
The impact of Vpu on the levels of cell-associated p24 varied (Fig. S3.4C), most likely because 
functional vpu genes may also enhance viral replication and thus increase the total number of 
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infected cells. Fully functional wt Vpus increased the total amount of p24 antigen produced in 
IFN-treated cultures by ~3-fold and this enhancement was severely impaired by the TMD 
mutations in Vpu (Fig. 3.3D). We quantified released p24 as the ratio of cell-free p24 divided by 
total p24. IFNαa treatment generally decreased the efficiency of virus release (Fig.3.3E). TMD 
mutations or the lack of Vpu function reduced virion release efficiency by ~20% in the absence 
and by ~50% in the presence of IFNa treatment (Fig. 3F). Although the Tmut Vpus failed to 
enhance virion release (Fig. 3.3E, 3.3F), they significantly enhanced total (Fig. 3.3D, S3.4B) p24 
production in the infected cultures.   
 
TF IMCs produce high titers of cell-free virus even in the absence of Vpu function. The data 
outlined above suggest that in addition to the anti-tetherin function, other activities of M-Vpus 
contribute to efficient viral replication in primary CD4+ T cells. However, the results shown in 
Figure 3.3 were only derived from a single time point (day 7) following HIV-1 infection. To further 
examine the importance of Vpu-mediated tetherin antagonism for HIV-1 replication, we monitored 
virus production in primary CD4+ T cells infected with wt and vpu mutant HIV-1 IMCs over a 
period of nine days (Fig. 3.4A). In addition, we included another CC HIV-1 IMC (STCO-CC) and 
the HIV-1 N DJO0131 clone in the analyses. As expected, TF HIV-1 strains CH058-TF and 
CH077-TF exhibited substantially higher levels of virus production than the remaining IMCs in the 
presence of IFNαa (Fig. 3.4A, 3.4B). On average, IFNαa treatment decreased virus yield of these 
two TF viruses ~9-fold, whereas that of the CC HIV-1 strains CH167-CC and STCO-CC was 47- 
and 75-fold, and that of the group N virus even >100-fold reduced (Fig. 3.4C).  
 The TMD mutations in Vpu resulted in cell-free virus yields that were intermediate between wt 
and vpu-defective HIV-1 group M strains in the absence of IFNαa treatment (Fig. 3.4B). In the 
presence of IFNαa, the Tmut Vpus failed to enhance the p24 levels in cultures infected with NL4-
3 or the CC strains, and had only modest effects on the two TF strains (Fig. 3.4B). Mutations in 
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the TMD or lack of Vpu function enhanced sensitivity of most HIV-1 M IMCs to IFNαa inhibition 
~3- to 4-fold (Fig. 3.4C). The exception was the STCO-CC strain, which showed low levels of 
replication and was highly susceptible to IFNα inhibition irrespective of Vpu function (Fig. 3.4C). 
The single group N virus was also very susceptible to IFN inhibition. Notably, the ~4-fold 
enhancement of p24 production by HIV-1 N Vpu in the presence of IFN was not impaired by the 
TMD mutations (Fig. 3.4A-C). Thus, N-Vpu appears to promote HIV-1 replication independent of 
its modest anti-tetherin activity. In contrast, the 5- to 9-fold enhancing effect of group M Vpus was 
disrupted by the TMD mutations (Fig. 3.4D). We ranked the HIV-1 IMCs based on their efficacy to 
produce cell-free virus (Fig. 3.4E). In the absence of IFN, the T-cell line adapted NL4-3 construct 
showed the highest virus yield and functional vpu genes had only modest effects on the levels of 
cell-free p24 (Fig. 3.4E). In contrast, TF HIV-1 IMCs produced the highest levels of cell-free p24 
in the presence of IFN. Mutations in the TMD domain or entire loss of Vpu function reduced cell-
free p24 yield from TF IMCs by 2.5- and 5-fold, respectively. However, even the vpu mutated or 
vpu-defective TF IMCs showed higher virus yields than the CC HIV-1 M and the group N strains 
(Fig. 3.4E, right). Thus, Vpu-mediated tetherin antagonism is critical for high virus yield from 
infected CD4+ T cells in the presence of IFNαa, but additional vpu-independent functions also 
play a role. 
 
TF IMC infected cells release virions with high efficacy even in the absence of Vpu 
function. Next, we determined the levels of cell-free and total p24 antigen in the cultures (Fig. 
S3.5) to calculate the efficiency of virus release. Unexpectedly, the Tmut HIV-1 M IMCs produced 
total quantities of p24 antigen that were as high (CH058-TF, STCO-CC) or slightly higher (NL4-3; 
CH077-TF, CH167-CC) than the p24 antigen amounts produced by the respective wt viruses 
(Fig. S3.5B), which may be due to more effective cell-to-cell spread and/or Vpu-mediated 
degradation of CD4 in Tmut infected cultures. In agreement with data shown in Figure 3.3, IFNαa 
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treatment reduced the efficiency of virus release, particularly in the absence of a functional Vpu. 
Furthermore, release of the TF HIV-1 IMCs was more efficient than that of CC viruses, while 
release of the HIV-1 group N DJO0131 IMC was markedly reduced relative to the five group M 
viruses (Fig. 3.5A). These differences in virion release were highly reproducible in independent 
experiments (Fig. S3.6). Interestingly, Tmut as well as vpu-defective TF HIV-1 strains showed 
significantly higher efficiencies of virion release than the wt CC HIV-1 strains in the presence of 
IFNαa  (Fig. 3.5A, 3.5B). In general, the differences in virion release capacity were much more 
pronounced in IFNαa-treated than in untreated CD4+ T cell cultures (Fig. 3.5C), but the relative 
efficiencies of the 18 HIV-1 IMCs measured under both conditions showed a highly significant 
correlation (Fig. 3.5D). CC HIV-1 IMCs containing disrupted or mutated vpu genes and all HIV-1 
group N constructs exhibited very low (<10% of wt TF HIV-1 IMCs) efficiencies of virion release 
(Fig. 3.5C, right). For all viruses, there was a significant correlation between p24 production and 
release, particularly in IFNαa-treated cultures (Fig. 3.5E, 3.5F), although other factors clearly also 
influence virus production. Finally, we examined whether the human specific adaptations in Vpu 
affected the infectiousness of viral particles produced in the infected CD4+ T cells cultures. We 
found that the TF derived virions were substantially more infectious than the CC and group N 
derived particles (Fig. S3.7A). The mutations in Vpu, however, had no significant effect on virion 
infectivity (Fig. S3.7B). Altogether, these results suggest that high infectivity and efficient virion 
release might represent hallmarks of TF HIV-1 strains and that the latter is only partly dependent 
on potent Vpu-mediated tetherin antagonism. 
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Section 3.5 – Discussion  
 
Great apes transmitted SIVs to humans on at least four independent occasions. However, only 
one of these transmission events resulted in a pandemically spreading pathogen (1). Elucidating 
the viral properties that mediate efficient spread of HIV-1 is important for preventive strategies. It 
has been suggested that the acquisition of Vpu-mediated tetherin antagonism promoted efficient 
spread of HIV/AIDS (10, 11). However, direct evidence for this hypothesis has been lacking 
because thus far only T-cell line adapted viruses have been characterized that were completely 
vpu-deficient. Here, we show that amino acid mutations in the TMD domain of Vpu, which are 
critical for anti-tetherin activity, reduce virion production and release in the presence of IFNαa by 
about 50%. Tmut TF viruses were released about 3-fold more efficiently than Tmut CC viruses, 
and >10-fold more efficiently than the Tmut group N virus in IFNa-treated human CD4+ T cells, 
although this release was only partly dependent on Vpu (Fig. 3.5C). Thus, our data support the 
hypothesis that adaptation at key Vpu residues that confer effective tetherin antagonism were 
indeed important for the spread of HIV/AIDS. Moreover, our data suggest that TF HIV-1 M strains 
have evolved additional yet-to-be-defined Vpu-independent functions to ensure efficient virus 
release and replication in the face of an innate antiviral response. 
 The TMD mutations in Vpu resulted in HIV-1 M virus levels that were intermediate between wt 
and vpu-defective IMCs, although in the presence of exogenous IFNαa this phenotype was 
almost identical to that of HIV-1 lacking Vpu entirely (Fig. 3.4A, 3.5B). However, in the absence of 
IFNαa, Tmut Vpus had little if any reducing effect on the total levels of HIV-1 p24 antigen 
production (Fig. S3.3B, S3.4B). The remaining activity of Tmut Vpus is unlikely due to residual 
anti-tetherin activity, since there were no significant differences in the amounts of particle release 
from TMD-mutated and Vpu deficient IMC infected cultures (Fig. 3.3F, 3.5A). Together, these 
data suggest that both the newly acquired anti-tetherin activity and other Vpu functions that are 
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conserved between HIV-1 and SIVcpz Vpus, such as degradation of CD4 or inhibition of NF-kB 
activation, increase viral replication fitness in primary CD4+ T cells. Lentiviral accessory proteins 
are well known for their multi-functionality, only some of which might be lost after cross-species 
transmission.  
 Although mutations in the TMD domain of Vpu and complete lack of Vpu function reduced the 
replication potential and particle release of TF viruses, particularly upon treatment with IFNαa, 
their growth rates and virion production capacity remained significantly higher than those of wt 
CC HIV-1 strains (Fig. 3.4, 3.5). Tetherin-independent effects on virus release are further 
supported by the reduced replication capacity of the CH167-CC IMC compared to the two TF 
viruses and HIV-1 NL4-3 (Fig. 3A, 4A), although its Vpu showed the highest potency in 
antagonizing tetherin (Fig. 3.1C) and enhancing p24 production (Fig. 3.3C, 3.4D). Moreover, the 
Vpu proteins of TF viruses are equally potent at antagonizing human tetherin than those derived 
from CC HIV-1 strains (33, 34). Thus, other as-yet-unknown viral properties that promote efficient 
release of virions from infected T cells likely contribute to virus spread. One of them is the ability 
to potently degrade and downmodulate CD4. It has been shown that CD4 inhibits virus release 
(35) and reduces virion infectivity (36, 37). The phenotype of the group HIV-1 N DJO0131 strain 
that lacks a Vpu-mediated CD4 degradation function (12) supports these findings. Potent CD4 
downmodulation are also consistent with previous data showing that TF virions are slightly more 
infectious and contain about two-fold more Env per particle than CC viruses (32). Although all 
IMCs efficiently down-modulated cell-surface CD4 due to functional Nef and Env expression, 
Vpu-mediated CD4 degradation may contribute to potent virus release and replication by 
preventing intracellular interaction between CD4 and the viral Env glycoprotein (35-37). However, 
other cellular factors that affect virion release efficacy, such as T-cell immunoglobulin (Ig) and 
mucin domain (TIM) proteins (38), may also play a role, and it will be interesting to determine 
whether they are efficiently counteracted by TF HIV-1. 
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 It is still unclear whether cell-free or cell-associated virus predominates in sexual HIV-1 
transmission (39, 40), although multiple studies found a correlation between the efficiency of 
transmission and levels of cell-free virus in blood or genital secretions (41-43). We found that TF 
viruses produced much higher levels of cell-free virus than CC HIV-1 M, whereas the levels of 
cell-associated virus were higher in the T cell cultures infected with the CH167-CC and group N 
DJO0131 viruses (Fig. S3.5A). Thus, it is possible that cell-free HIV-1 plays an important role in 
sexual virus transmission. 
 The group N HIV-1 molecular clone was highly sensitive to IFN inhibition and produced very 
little cell-free virus in the presence of IFN (Fig. 3.4E), although the levels of cell-associated p24 
antigen and total produced virus were comparable to that of the two TF HIV-1 M strains both in 
the presence and absence of IFNαa (Fig. S3.5). However, in the presence of IFN both wt and 
TMD mutated group N Vpus increased cell-free virus production about 4-fold (Fig. 3.4D). Thus, it 
seems clear that the DJO (N) Vpu promotes virus production by yet-to-be-defined tetherin-
independent mechanisms. Whether these effects of N-Vpu contribute to viral pathogenesis 
remains to be determined but it is noteworthy that HIV-1 N strains can cause CD4+ T cell 
depletion and AIDS (44-46). 
 In summary, our results demonstrate that Vpu-mediated tetherin antagonism enhances virus 
production and release from primary CD4+ T cells by about 5-fold in the presence of high levels 
of type I IFN. We further show that even vpu-defective or mutated TF HIV-1 strains exhibit higher 
virion release capacity than wt CC HIV-1 strains in IFNαa-treated primary T cells. Thus, TF HIV-1 
M vpu genes appear to encode functions in addition to effective tetherin antagonism that enhance 
viral replication and release in the presence IFN. Finally, CD4 T cell infected with wt group N virus 
produced about 4-fold less cell-free virions compared to CC HIV-1 M strains and about 13-fold 
less virions compared to TF HIV-1 M IMCs. Thus, the efficiency with which virus is released from 
infected CD4 T cells appears to be correlated with the ability of HIV-1 to spread in humans, with 
anti-tetherin activity playing a major role at least for group M viruses. 
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Section 3.6 - Materials and methods 
 
HIV-1 proviral constructs. Generation of NL4-3, CH058, CH077, CH167, STCO and group N 
DJO0131 HIV-1 IMCs has been previously described (12, 25, 26, 32, 47) (Table S1). Site-
directed mutagenesis of vpu was performed by splice overlap extension PCR and all constructs 
were verified by sequence analysis. TMD mutations in Vpu are shown in Fig. 3.1A. Grossly vpu-
defective IMCs contained a premature stop codon at amino acid positions two and three of the 
vpu reading frame, except NL4-3 that contained a 120 bp deletion in vpu.  
Expression vectors. Cloning of HIV-1 vpu genes and human tetherin, CD4, NTB-A and CD1d 
alleles into the bi-cistronic CMV promoter-based pCG expression vector coexpressing the green 
fluorescent protein (GFP) was performed as described previously (5, 12). 
Cell culture. HEK293T cells were maintained in Dulbecco’s modified Eagle medium (DMEM) 
supplemented with 10% heat-inactivated fetal bovine serum, 350 µg/ml L-glutamine, 100 µg/ml 
streptomycin sulfate and 100 U/ml penicillin. HEK293T cells were transfected by the calcium 
phosphate method. Human peripheral blood mononuclear cells (PBMC) from healthy donors 
were isolated using lymphocyte separation medium (Biocoll Separating Solution, Biochrom), 
stimulated for 3 days with PHA (1 µg/ml) and cultured in RPMI1640 medium with 10% FCS and 
10 ng/ml IL-2 prior to infection. 
Flow cytometric analysis. To determine the effect of Vpu on CD4, CD1d, NTB-A and tetherin 
cell surface expression, HEK293T cells were transfected by the calcium phosphate method with 1 
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µg of a CD4, CD1d, NTB-A, or tetherin expression vector and 5 µg of pCG eGFP/Vpu constructs 
expressing eGFP alone or together with Vpu. Two days post-transfection CD4, CD1d, NTB-A or 
tetherin expression was examined by FACS analysis. An allophycocyanin-conjugated anti-human 
tetherin antibody (Biolegend), allophycocyanin-conjugated anti-human CD4 antibody (Invitrogen; 
MHCD0405), a phycoerythrin-conjugated anti-CD1d antibody (BD 550255) or an APC-conjugated 
anti-SLAM6 antibody (R&D FAB19081A) was used for staining. Fluorescence of stained cells was 
detected by two-color flow cytometry and Vpu-mediated CD4, CD1d, NTB-A or tetherin down-
modulation was calculated as described previously for the functional analysis of nef alleles (48). 
To determine the effect of Vpu on tetherin surface expression levels in primary cells, PHA-
stimulated PBMCs were transduced by spinoculation (2 h at 37°C, 1300 x g) with VSVg-
pseudotyped HIV-1 proviral constructs. Three days after transduction, PBMCs were dual stained 
for surface tetherin (allophycocyanin-conjugated anti-human tetherin antibody from Biolegend) 
and CD4 (phycoerythrin-conjugated anti-human CD4 from Invitrogen MHCD0404), permeabilized 
and stained intracellularly for p24 with a FITC-conjugated antibody (Beckman coulter). 
Western blot. To monitor Vpu expression, 293T cells were transfected with 5 µg of vector DNA 
co-expressing eGFP and AU-1 tagged Vpus. The vpu alleles were not codon-optimized. Two 
days post-transfection cells were harvested, lysed in CO-IP buffer (150 mM NaCl, 50 mM 
HEPES, 5 mM EDTA, 0.1% NP40, 0.5 mM sodium orthovanadate, 0.5 mM NaF, pH 7,5) and cell 
lysates were separated in 4-12% Bis-Tris gels (Invitrogen). After gel electrophoresis, proteins 
were transferred onto PVDF membranes and probed with AU-1 antibody (Covance, MMS-130P). 
Subsequently, blots were probed with anti-mouse or anti-rabbit IRDye Odyssey antibodies (926-
32210, 926-32221) and proteins detected using a LI-COR Odyssey scanner. For internal controls, 
blots were incubated with antibodies specific for eGFP (290-50, Abcam) and β-actin (8227-50, 
Abcam). 
Tetherin antagonism in HEK293 cells. To determine the capability of Vpu to antagonize 
tetherin, 293T cells were seeded in six-well plates and transfected with 2 µg of NL4-3 ΔVpu IRES 
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eGFP, 500 ng Vpu expression plasmid and different dilutions of tetherin expression plasmid. A 
pCGCG vector expressing eGFP only was used to equalize the DNA concentrations. At two days 
post-transfection supernatants were harvested and the yield of infectious HIV-1 was determined 
by a 96-well infection assay on TZM-bl indicator cells as described previously (49). 
Inhibition of NF-kB activity. To determine the effect of Vpu on NF-κB activity, HEK293T cells in 
96-well format were co-transfected in triplicates with 0.1 µg firefly luciferase reporter construct 
under the control of three NF-κB binding sites, 0.025 µg Gaussia luciferase construct under the 
control of a minimal pTAL promoter for normalization, and 0.04 µg expression vectors for a 
mutant of IKKβ containing two phosphomimetic changes (S177E, S181E) in the activation loop 
that render the expressed protein constitutively active or increasing concentration of tetherin, as 
well as 0.025 µg pCGCG eGFP/Vpu. Dual luciferase assays were performed 48 h post-
transfection and the firefly luciferase signals were normalized to the internal Gaussia luciferase 
control as described (19). 
Viral replication in CD4+ T cells. To assess the contribution of tetherin antagonism to the IFN 
resistance of full-length IMCs, we generated virus stocks of wildtype, Tmut and vpu- IMCs by 
transfection of 293T cells. CD4+ T-cells were positively selected (Miltenyi Biotec) from buffy coats 
of 3 healthy donors (Research blood components). Cells were activated by anti- CD2/CD3/CD28 
beads (Miltenyi Biotec) and cultured in cell culture media (RPMI 15% FBS, 1X PSG + IL-2 (30 
U/ml)) for 4 days at 37 oC and 5% CO2. Cells were pooled and either treated with 500 U/ml of 
IFNα2 (PBL Assay Science) or left untreated. Cells were infected with normalized amounts of 
virus in small volumes (250 µl) overnight (12-15 h). Cells were washed with PBS (3x) and 
resuspended in cell culture media. Every 48 hours, supernatants were sampled for cell- free p24 
measurements, and media (-/+ IFN) was added back. To quantify cell- associated p24, we 
harvested cells at days 7 and 9 and resuspended cells in lysis buffer. Cell-free and cell-
associated p24 antigen levels were quantified using the commercially available p24 AlphaLisa 
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(Perkin Elmer). Each virus was tested in duplicate per experiment and experiments were 
repeated twice in two separate pools of CD4+ T-cells. 
Virion infectivity. 8.300 TZM-bl cells were seeded per well in a 96-well plate. At a confluence of 
~ 40%, the cells were infected with 100 µl of cell-free supernatant of infected CD4+ T cells 
obtained 7 days post-infection in the presence of DEAE-dextran (final 40ug/ml). 48 hours later, 
the cells were lysed (Promega E153A), lysates were frozen at -80 oC for 2 hours and relative light 
units (RLU) were determined using the luciferase assay system (Promega). The RLUs obtained 
were normalized to the capsid antigen p24 levels to obtain RLUs per pg p24 capsid antigen. Each 
measurement was performed in duplicate. 
Ethics statement. Ethical approval for the utilization of human-derived cells was obtained from 
the Ethics Committee of Ulm University Medical Center.  
Statistical analysis. Statistical calculations were performed using two-tailed unpaired (for 
comparison of different groups) or paired Student’s-t-tests using Graph Pad Prism Version 5.0. 
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Section 3.9 – Chapter Tables and Figures  
 
Table 3.1. Infectious molecular clones of HIV-1 analyzed. 
 
Clone Group  Subtype Type Tropism Vpu length    Mutations  
Reference 
HIV-1 NL4-3  M B lab-ad. X4 81aa A14L, A18L (44) 
HIV-1 CH058  M B T/F R5 80aa A14L, A18L (32) 
HIV-1 CH077  M B T/F R5 81aa A15L, A19L (32) 
HIV-1 STCO   M B CC R5 81aa A15L, A19L (32) 
HIV-1 CH0167  M C CC R5 84aa A20L, A24L (32) 
HIV-1 DJO0131  N - n.k. n.k. 74aa A12L, A16L (12) 
n.k., not known 
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FIG 3.1. Mutant Vpus selectively defective in tetherin antagonism. (A) Alignment of Vpu amino 
acid sequences analyzed. The NL4-3 Vpu sequence is shown on top for comparison. Important 
functional domains are indicated and the mutated Ala residues are highlighted in yellow. Dots 
specify amino acid identity and dashes represent gaps introduced to optimize the alignment. (B) 
Downmodulation of human tetherin by wt and mutant Vpu proteins in HEK293T cells 
cotransfected with vectors coexpressing eGFP and Vpu and a construct expressing human 
tetherin. Shown are the levels of tetherin cell surface expression relative to those measured in 
cells transfected with the eGFP only control vector (100%). Shown are mean values (±SEM) 
derived from three experiments. Wt Vpu alleles are color coded in dark colors and mutant Vpus in 
light colors. *, p<0.05; **, p<0.01; ***, p<0.001. (C) Virus release from HEK293T cells following 
transfection with vpu-defective HIV-1 NL4-3, expression constructs for the indicated Vpu proteins 
or eGFP only and varying amounts of plasmid expressing human tetherin. Infectious virus was 
determined by infection of TZM-bl indicator cells and is shown as a percentage of that detected in 
the absence of tetherin (100%). Infections were performed in triplicate and the results were 
confirmed in an independent experiment.  
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FIG 3.2. TMD mutations in Vpu disrupt tetherin downmodulation in HIV-1 infected primary T cells. 
PHA-activated PBMCs were infected with HIV-1 constructs containing wt, TMD mutated or 
grossly defective vpu alleles and examined for tetherin surface expression 3 days later. Panel A 
provides examples of primary data and the panel B the levels of tetherin surface expression in 
cells infected with the wt and Vpu mutant constructs relative to those infected with the vpu-
defective HIV-1 constructs (100%). Each symbol represents the result obtained for one individual 
PBMC donor investigated. The numbers in panel A give the mean fluorescence intensity (MFI) of 
tetherin expression in the HIV-1 infected (p24+) cell population. ∗∗∗ indicates that wt Vpus are 
significantly (p < 0.001) more active than the TMD mutant Vpus.   
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FIG 3.3. Effect of alterations in vpu on HIV-1 yield and release in CD4+ T cells in the presence or 
absence of IFNα. (A) p24 antigen levels in the supernatant of CD4+ T cells at day 7 post-infection 
with HIV-1 IMCs expressing wt (+), Tmut (m) or no (-) Vpu proteins. Virus yield was determined 
after triplicate HIV-1 infection in the absence (left) and presence (right) of 500 U/ml IFN-α. (B) 
Reduction of cell-free p24 antigen yield by IFN-α treatment. For calculation of n-fold reduction, 
the levels of p24 antigen obtained in the absence of IFN were divided by those obtained in the 
presence of IFN-α. (C) Enhancement of p24 release by wt and Tmut Vpu proteins in the absence 
or presence (shaded) of exogenous IFN-α. Data were derived from the experiment shown in 
panel A. Shown are the levels of cell-free p24 antigen relative to the cultures infected with the 
respective vpu-defective HIV-1 IMCs (100%, indicated by the dashed line). (D) Cell-free, cell-
associated and total p24 yield in CD4+ T cells infected with HIV-1 NL4-3, CH058-TF, CH077-TF 
and CH167 IMCs containing wt, mutant or grossly defective vpu genes. The average values 
obtained for the respective wt IMCs were set to 100%. (E) Efficiency of p24 release in CD4+ T 
cells infected with the indicated HIV-1 IMCs. Values present percentages of cell-free p24 antigen 
out of the total p24 detected in the absence and presence (shaded) of IFN-α. Cell-free and cell-
associated p24 antigen were quantified by ELISA at day 7 post-infection. (F). Effect of TMD 
mutations in Vpu or entire lack of Vpu function on the efficiency of virion release. Values obtained 
for all four IMCs analyzed are shown relative to the respective wt viruses (100%).  
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FIG 3.4. Replication of wt and vpu mutant HIV-1 constructs in CD4+ T cells in the presence and 
absence of IFN-α. (A) Replication kinetics of HIV-1 IMCs expressing wt, TMD mutant or no Vpu 
proteins in CD4+ T cells in the absence (black lines) and presence (blue lines) of 500 U/ml IFNα. 
Results show median values of p24 antigen production (n=3) from two different donors. (B) 
Cumulative p24 antigen levels in the absence (left) and presence (right) of IFN-α measured at 1, 
3, 5, 7 and 9 days post-infection. Panels B, C and D show the results obtained from two different 
blood donors. (C) Reduction of cumulative cell-free p24 antigen yield by IFN-α treatment. (D) 
Enhancement of cumulative p24 yield by wt and Tmut Vpu proteins in the absence or presence 
(shaded) of exogenous IFN-α. Data were derived from the experiment shown in panel A. Values 
present total cell-free virus yield relative to the respective vpu-defective HIV-1 IMC (100%). (E) 
Ranking of wt and vpu mutant or defective HIV-1 IMCs according to their efficiency in cell-free 
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p24 production. The levels achieved for the most potent IMC were set to 100%. Shown are 
median values of p24 antigen production (±SEM, n=3).  
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FIG 3.5. Release of wt and vpu mutant HIV-1 constructs in CD4+ T cells in the presence and 
absence of IFN-α. (A) Values present percentages of cell-free p24 antigen out of the total p24 
detected in the presence and absence of IFN-α. Triplicate infections of T cells derived from three 
PBMC donors are shown. Cell-free and cell-associated p24 antigen was quantified by ELISA at 
day 5 post-infection. (B) Efficiency of TF and CC virus release in CD4+ T cells infected with the 
indicated HIV-1 IMCs. Values present percentages of cell-free p24 antigen out of the total p24 
detected in the absence and presence (shaded) of IFN-α. (C) Ranking of wt and vpu mutant or 
defective HIV-1 IMCs according to their release efficiency. The levels achieved by the most 
potent IMCs were set to 100%. Shown are median values of release efficacy (±SEM, n=3). (D) 
Correlation between the virus release efficiencies measured in the absence and presence of IFN-
a. (E, F) Correlation between the virus release efficiencies (values derived from panel C) and p24 
antigen yield (values derived from Fig. 3.4E) in the absence (E) and presence (F) of IFN-a.  
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Section 3.10 Chapter supplemental material 
 
 
SUPPLEMENTAL MATERIAL 
FIG S3.1. Expression and tetherin, CD4, NTB-A and CD1a downmodulation activities of TMD 
mutant Vpu proteins. 
FIG S3.2. Inhibition of NF-κB activation by wt and Tmut Vpu proteins. 
FIG S3.3. Downmodulation of CD4 in PBMCs infected with HIV-1 IMCs differing in their vpu 
coding sequences. 
FIG S3.4. Effect of alterations in vpu on cell-associated and total HIV-1 yield in the presence and 
absence of IFNα. 
FIG S3.5. Effect of alterations in vpu on cumulative cell-associated and total p24 production in the 
presence and absence of IFNα. 
FIG S3.6. Differences in virion release efficacy are highly reproducible. 
FIG S3.7. Infectivity of HIV-1 IMCs produced in CD4+ T cells   
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Supplemental Figures 
  
 
FIG S3.1. Expression and tetherin, CD4, NTB-A and CD1a downmodulation activities of TMD 
mutant Vpu proteins. (A) HEK293T cells were transfected with plasmids encoding the indicated 
AU1-tagged Vpus and analyzed by Western blot. An empty vector and mock transfected cells 
were used as negative controls. The vpu alleles were not codon-optimized. (B) FACS analysis of 
HEK293T cells cotransfected with tetherin or CD4 expression vectors and pCG plasmids 
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expressing eGFP alone (lanes 2 and 3) or together with the indicated vpu allele. The mean 
fluorescence intensities (MFIs) are indicated. (C-E) Vpu-dependent reduction of (C) CD4, (D) 
NTB-A and (E) CD1d and surface expression in HEK293T cells. Shown are the levels of receptor 
cell surface expression relative to those measured in cells transfected with the eGFP control 
vector. Shown are mean values (±SEM) derived from three experiments. Wt vpu alleles are 
indicated by dark and Tmut Vpu by light colors. 
 
 
 
 
FIG S3.2. Inhibition of NF-κB activation by wt and Tmut Vpu proteins. (A) HEK293T cells were 
cotransfected with the indicated vpu alleles, a firefly luciferase reporter construct under the 
control of three NF-kB binding sites, a Gaussia luciferase construct for normalization, and 
expression vectors for a constitutively active mutant of IKKb as inducer of NF-κB. Luciferase 
activities were determined 48 h post-transfection. Shown are mean values (±SEM) derived from 3 
experiments. (B) HEK293T cells were transfected as described in panel A, except that different 
quantities of tetherin expression vectors were used to induce NF-κB activation.  
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FIG S3.3. Downmodulation of CD4 in PBMCs infected with HIV-1 IMCs differing in their vpu 
coding sequences. PHA-activated PBMCs were transduced with the indicated VSV-G 
pseudotyped HIV-1 IMCs and examined for CD4 surface expression 3 days later. Panel A shows 
examples of primary FACS data. Numbers give mean fluorescence intensities (MFI) of CD4 
expression in the HIV-1 infected (p24+) cell population. Panel B shows the levels of surface 
expression in virally infected (p24+) cells relative to uninfected cells (100%). Each symbol 
provides the result obtained for one individual PBMC donor. 
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FIG S3.4. Effect of alterations in vpu on cell-associated and total HIV-1 yield in the presence and 
absence of IFNα. (A) Cell-associated and (B) total p24 antigen levels in CD4+ T cells at day 7 
post-infection with HIV-1 IMCs expressing wt (+), Tmut (m) or no (-) Vpu proteins. P24 levels 
were determined by ELISA after triplicate HIV-1 infection in the absence (left) and presence 
(right) of 500 U/ml IFN-α. (C, D) Enhancement of (C) cell-associated and (D) total p24 antigen 
levels by wt and Tmut Vpu proteins in the absence or presence (shaded) of exogenous IFN-α. 
Data were derived from the experiment shown in panels A and B. Shown are the levels of cell-
associated and total p24 antigen relative to the cultures infected with the respective vpu-defective 
HIV-1 IMCs (100%, indicated by the dashed line.  
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FIG S3.5. Effect of alterations in vpu on cumulative cell-associated and total p24 production in the 
presence and absence of IFNα. (A) Cumulative cell-associated and (B) total p24 antigen levels in 
CD4+ T cells at 5, 7 and 9 days post-infection with HIV-1 IMCs expressing wt (+), Tmut (m) or no 
(-) Vpu proteins. P24 levels were determined by ELISA in the absence (left) and presence (right) 
of 500 U/ml IFN-α. 
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FIG S3.6. Differences in virion release efficacy are highly reproducible. Correlation between the 
release efficiencies at day 7 post-infection in the experiment shown in Fig. 3.3E and average 
values obtained at 5, 7 and 9 days post-infection in an independent experiment (Fig. 3.5A) in the 
absence (left) and presence (right) of IFN-a treatment. 
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FIG S3.7. Infectivity of HIV-1 IMCs produced in infected CD4+ T cells. (A) Infectivity of HIV-1 
IMCs expressing wt, Tmut or no (-) Vpu proteins obtained from infected CD4+ T cells at  day 7 
post-infection. Values represent averages of duplicate infection and were obtained in the absence 
of IFN-α treatment. (B) Infectivity of the HIV-1 IMCs shown in panel A grouped based on their vpu 
coding sequences. Shown are minimum and maximum values, 25% and 75% percentiles, and 
median values. 
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Section 4.1 
 
Mucosal HIV-1 transmission and resistance to type I Interferons 
 
 
Mucosal transmission of HIV-1 is characterized by a stringent bottleneck where ~80% of 
infections are founded by a single variant (1-4). This finding coupled with the observation that 
more ancestral viral genomes are preferentially transmitted, led to the hypothesis that mucosal 
infection selects for viruses with increased fitness (5-8). However, the determinants of this viral 
fitness have not been identified.  
 
To determine biological properties of transmitted founder (TF) viruses, it is important to 
have full-length replication competent viruses and a good set of controls. The inference of the TF 
sequence is generally straight forward (1, 3, 9-12), however the selection of the chronic viruses 
for comparision is not (13-15). Parrish and colleagues identified clusters of near identical 
sequences in chronically infected individuals (rakes) and constructed infectious molecular clones 
(IMCs) matching the consensus sequences of these rakes(16). This approach makes the 
reasonable assumption that common ancestors of each rake represents a replication-competent 
and therefore biologically relevant virus. In two subsequent studies using transmission pairs (17, 
18), the authors also constructed IMCs, but picked random viral genomes from chronically 
infected individuals to compare to TF IMCs. With this method, there is no evidence of the in-vivo 
functionality and relevance of the chronic control viruses (19).  
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In the pursuit of transmitted phenotypes, transmission pairs are ideal, as they enable the 
direct comparison of the TF virus to the quasispecies that it was derived from. These 
comparisons are thus controlled for virological and host factors with the caveat that sampling at 
the time of transmission is not feasible and hence a temporal gap exists between transmission 
and the availability of samples for study. The next consideration is how to represent the genetic 
and therefore, biological diversity of the viruses infecting a chronic donor. Previous studies have 
compared a limited number (1-2) of chronic viruses to the matched TF in many assays (17, 18). 
Under these conditions, limited sampling can cause inaccurate or incomplete results. The ideal 
study would assemble panels of multiple chronic viruses to compare to each TF virus.  
 
To this end, in chapter 2, I compared the biological properties of 300 viruses from donors 
and recipients of mucosal transmission pairs. Subjects with stringent mucosal bottlenecks 
characterized by the transmission of a single (7 out of 8) or two (1 out of 8) variants were 
selected. In all but one pair, the acutely infected recipient was identified first and the donor was 
identified and enrolled retrospectively. In the last pair, the donor transmitted to two recipients, and 
the second recipient was sampled shortly after the donor (median time between the donor and 
recipient samples was 65 days). The selected transmission pairs represented different routes of 
transmission (male to female, MTF; female to male, FTM; and men who have sex with men, 
MSM) and both, subtype B and C infections.  
 
The construction of IMCs is time-consuming and expensive, and requires the authors to 
choose a method to generate chronic controls. To derive viruses while avoiding these concerns, I 
generated virus isolates by limiting-dilution of donor and recipient plasma. Isolates generated by 
this method are derived from a single viral variant and in addition, I was able to generate similar 
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viral isolates from genital secretion samples of 3 donors. This study is the first to characterize the 
biology of full-length viruses from the genital compartment.  
 
In my analysis, I found that recipient viruses had comparable levels of envelope 
glycoprotein, yet were more infectious, replicated to higher titers in primary cells, were released 
more efficiently from infected cells and displayed enhanced resistance to the antiviral effects of 
IFNα2 and IFNβ when compared to donor plasma viruses. In addition, recipient viruses replicated 
more efficiently in the presence of maximal doses of IFNα2 and IFNβ than donor plasma viruses. 
Interestingly, donor genital tract viruses were more infectious and were more resistant to IFNα2 
than donor plasma viruses. Thus there were biological differences in plasma and genital tract 
viruses, despite the lack of compartmentalization of the viral sequences. I reasoned that 
chronically infected donors must harbor IFN resistant viruses so as to transmit them to the 
matched recipients. To identify these viruses, and in part re-create hurdles observed in-vivo, I 
pre-treated CD4+ T-cells with IFNα2 and IFNβ prior to generating chronic donor plasma isolates. 
I found that IFN b selected isolates, and not IFNα2 selected ones were phenotypically similar to 
recipient viruses.  Thus transmitted viruses are phenotypically distinct, and resistance to type I 
IFNs is their most characteristic property and these findings are summarized in Fig 1 (modified 
from (20)).  
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High Transmission Fitness (R0 >>1)
High particle infectivity
High replicative capacity
Efficient release from cells
Resistance to type I interferons 
Low Transmission Fitness (R0 >>1)
Low particle infectivity
Low replicative capacity
Inefficient release from cells
Sensitivity to type I interferons 
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Figure 4.1 Model of the HIV-1 mucosal bottleneck. Mucosal transmission of HIV-1 is associated 
with a stringent genetic bottleneck, where only one or very few variants from the donor 
quasispeces found infection in the new recipient. Viruses with enhanced particle infectivity, 
replicative capacity, IFNα and IFNβ resistance and release are selected for during mucosal 
transmission.   
 
In contrast to results from Parrish and colleagues, I did not find all recipient viruses to 
incorporate more Env than matched donor viruses and hence this property is not a generalizable 
feature of TFs. However, in 3 out of 8 pairs, recipient viruses did contain more Env. This suggests 
that under certain circumstances, variants with increased Env content have an advantage at 
transmission. Increased levels of Env could cause more stable attachment to target cells(21), or 
make up for loss due to shedding or overcome inactivation by genital secretions (22, 23). I 
observed that recipient viruses replicated more efficiently than matched donor viruses, suggesting 
that interventions that reduce the reproductive ratio (R0) by even a modest degree could impact 
early steps following transmission (24). The observation that recipient viruses are released more 
efficiently from infected cells is intriguing. Differences between donor and recipient viruses at 
multiple stages of the viral life cycle can contribute to the observed result. There could be a 
difference in the number of infected cells, which would determine the initial foci of infection. In 
addition, each infected cell could produce different numbers of viral particles (burst sizes), 
resulting in differences in both particle accumulation and subsequent rounds of infection (25-28). 
Modest differences in either or both of these could impact in-vivo outcomes substantially, 
especially given the exponential replication in the acute phase of infection (29-33).  
 
Previous studies suggest that the TF is a minor variant in the chronic quasispecies (34), 
and our results in Chapter 2, show that TF viruses are phenotypically distinct. It will thus be 
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important to understand the basis for these differences. A large amount of sequence information 
was generated in this study, and it will be interesting to attempt to identify signatures that 
associate with IFN resistance and other biological properties. Signature analysis for HIV-1 is 
complicated and requires a large number of sequences (35, 36), however, analysis by 
transmission pair could reduce inter-person variability.  
 Consistent with the cytokine storm observed during acute HIV-1 infection (32), transmitted 
viruses were more resistant to IFNα2 and IFNβ. In the earliest stages of viral infection, elevations 
in the levels of these antiviral cytokines can extinguish foci of IFN sensitive viruses (37)(Estes 
personal communication). Under these conditions, the residual viral replication at the maximal 
IFN dose is particularly telling, where recipient viruses are able to replicate, while donor viruses 
cannot. The ability to isolate IFN selected viruses suggest that IFN resistant viruses are 
maintained during chronic infection. Mutations associated with the loss of IFN resistance arise in 
part, due to the escape from neutralizing antibody (38) and cytotoxic T-lymphocyte pressure (SI 
unpublished). Given this, it is important to identify the reason for the maintenance of these IFN 
resistant viruses. It is possible that these viruses are present in the latent reservoir, and thus 
shielded from adaptive immune pressure. A recent study showed that the latent reservoir is 
seeded very early in infection (39, 40) and might be continually re-seeded during the course of 
infection and the genetic diversity we observed among IFN selected viruses would support the 
latter. Current HIV cure efforts aim to combine IFN therapy with broadly neutralizing antibodies 
(bNAbs) (41) after the activation of viruses from latency, to block subsequent infection and reduce 
the size of the latent reservoir (42). Hence, it would be very important to determine the level of 
pre-existing IFN resistance in the latent reservoir. 
 
In our previous study (43) we observed a difference between TF viruses from subtypes B 
and C. While TF HIV-1 from subtype B were ~60-fold more resistant to IFNα2 than chronic 
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viruses, subtype C TFs were comparable to subtype-matched chronic controls, with chronic 
viruses displaying unexpectedly high levels of IFN resistance. This raised the possibility that there 
might be differences between virus subtypes or differences between the cohorts studied. 
However, in chapter 2, I did not find a difference between subtype B and C transmission pairs, 
and hence the previously observed difference is likely patient-specific. It is possible that the 
chronically infected individuals studied by Parrish and colleagues were late in their disease 
course allowing for the reacquisition of IFN resistance (44, 45). In fact, our unpublished results 
support this hypothesis, with 4 longitudinally followed individuals displaying the expected rapid 
loss of IFN resistance within the first year of infection (37)(own unpublished observations), 
followed by the reacquisition of IFN resistance ~3 years following infection (Gondim and Hahn, 
unpublished observations). Thus, these data would suggest that IFN resistance is dynamic over 
the course of infection, and that the acute phase and late stage of infection are highly 
transmissible with high viral loads (46-49) and IFN resistant viruses.  
 
Many of our observations were consistent for both IFNα2 and IFNβ, yet I also observed 
differences in the antiviral potencies of the two IFN subtypes tested. Despite signaling through the 
same receptor (50), IFNα2 and IFNβ are reported to have varied downstream effects (51-54), 
consistent with what I observed in this study. I hypothesized that the two IFN subtypes would 
induce the expression of different sets of interferon stimulated genes, therefore leading to the 
different downstream outcomes. To test this, I performed a microarray experiment where I treated 
CD4+ T cells with both IFN subtypes for 24 hours and used untreated cells as a control. To my 
surprise, I did not find large differences in the numbers and nature of induced transcripts. In fact, 
only 15 genes were differentially induced (> 1.5-fold) by the two IFN subtypes. There are a few 
potential explanations for these observations. It is possible that the differences between the IFN 
subtypes are not visible at the level of RNA transcripts, but are due to differences in protein 
expression or RNA stability. However, our preliminary data suggests that protein levels of an ISG, 
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protein kinase R, are comparable across IFN subtypes (Persephone Borrow, personal 
communication). While this might not be generalizable for all ISGs, it suggests that other 
mechanisms must exist to account for the different downstream effects of interferon receptor 
(IFNAR) binding. One possibility is the modification of proteins by ubiquitylation or ISGylation. 
Both of these involve the non-covalent attachment of a small moiety (either ubiquitin or ISG15, 
respectively) to the protein of interest. The consequence of this modification can range from 
degradation to enhanced functionality (55-58). Type I IFNs can induce the expression of non-
coding RNA and therefore by extension, different IFN subtypes might induce distinct non-coding 
RNAs (59-66). Similar to protein modification, non-coding RNAs can have diverse downstream 
effects including impacting the stability of transcripts and efficiency of translation (67)m(68). In 
cases of invading pathogens and the necessity of a prompt immune response, the use of non-
coding RNA and protein modification to alter or enhance existing transcripts and proteins, and to 
subtly direct different responses by different IFN subtypes might be advantageous (66). To 
determine if there are differences in protein modification due to different IFN subtypes, we could 
use mass spectrometry or SILAC and to identify non-coding RNA species differentially modulated 
by IFN subtypes, RNA sequencing (RNAseq) could also be utilized. It is likely that cells respond 
to IFN in a heterogenous manner. This could obscure differences at the DNA, RNA or protein 
level unless analyzed at the level of the responding cell. In order to detect more subtle changes, it 
will be important to differentiate IFN responsive cells and perform downstream analysis on these 
cells to maximize the likelihood of identifying IFN subtype specific effects. 
 
I found that recipient viruses were on average 5-fold more resistant to IFNα2, but ~40-
fold more resistant to IFNβ than donor viruses. Harper and colleagues have quantified the IFN 
subtypes produced after incubating plasmacytoid DC (pDC) with HIV-1 (69). It will be both 
interesting and important to determine if recipient viruses are uniformly resistant to all the 
produced subtypes, and whether there are certain subtypes of IFN to which donor and recipient 
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viruses have equal levels of resistance. If we identify such subtypes, we can identify differentially 
modulated ISGs that are important during transmission. The identification of a set of critical ISGs 
can then be used to assess vaccination strategies that can selectively upregulate them in target 
CD4+ T cells or to define small molecules that interfere with viral counteraction of the ISG (70, 
71). As previously mentioned, type I IFNs, particularly IFNα2 is being evaluated in combination 
with bNAbs for a functional cure for HIV. Our data, consistent with data from Veazey and 
colleagues (72) indicates that IFNβ is more potently antiviral, and that chronic viruses have 
increased sensitivity to IFN b. Thus, it would be important to evaluate IFNβ and possibly, other 
IFN subtypes for their efficacy in reducing the HIV-1 reservoir.  
 
Lastly, it will be useful to determine if the selection of IFN resistant viruses at 
transmission can be recapitulated in the bone marrow liver thymus (BLT) mouse model. This 
humanized mouse model is repopulated with T and B cells, DC and natural killer (NK) cells of 
human origin, and is considered the best mouse model for HIV-1 transmission studies (73). I 
have previously shown that we can infect these mice (n=30) by vaginal routes and reproduce the 
bottleneck, characteristic of mucosal HIV-1 transmission in humans. However, in contrast to 
acutely infected humans, I observed only a modest increase in plasma IFN levels upon infection. 
This might be due to less efficient signaling from the mouse epithelium to recruit human immune 
cells upon contact with virus. I next determined if exogenous administration of IFN would be 
effective. I found that intraperitoneal injection of pegylated IFNα2 resulted in the induction of anti-
HIV-1 ISGs in the vaginal mucosa in a dose-dependent manner. Since I found IFNβ to distinguish 
recipient and donor viruses more strongly, I propose to administer IFNβ to the BLT mice prior to 
an intra-vaginal exposure to a pool of IFN sensitive and resistant viruses. I predict that in mice 
treated with IFNβ, only IFN resistant viruses will be selected for during transmission. Additionally, 
from our previous efforts to identify critical ISGs that impact transmission, we can transduce the 
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cells used to repopulate the BLT mice to over express candidate ISGs. Thus, we can evaluate 
their importance to transmission.  
 
In summary, my works shows that TF viruses are characterized by a set of biological 
properties that distinguish them from non-transmitted chronic viral variants. This argues against 
the stochastic nature of transmission. The most distinguishing property of TF viruses is their 
resistance to IFN. This would imply, that both the mucosal barrier and forces acting on the 
transmitted virus beyond the mucosal barrier in combination, select for the TF virus.  The 
increased resistance to IFN indicates that TF viruses overcome restriction by interferon-
stimulated genes more effectively than chronic non-transmitted viruses. We explored this 
hypothesis in Chapter 3 and the results and future directions are discussed in section 4.2 below. 
 
Section 4.2  
 
Viral accessory proteins and their counteraction of interferon stimulated genes 
 
Continuous interactions with various viral pathogens have shaped the evolution of 
antiviral restriction factors (74, 75). These host factors are induced by Type I IFNs and act to 
inhibit multiple steps of the viral life cycle. Underscoring the importance of these restriction 
factors, are the multiple viral proteins dedicated to their counteraction (75, 76). The interactions 
between host restriction factors and their viral antagonists can influence both within species and 
cross-species transmission events. In fact, it has been suggested that the ability to overcome the 
host protein tetherin was an important factor in the spread of Group M HIV-1 (77).  
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Pandemic group M HIV-1 strains use Vpu to counteract tetherin resulting in efficient 
released from infected cells(78, 79). Multiple studies have shown that the antiviral state 
established by type I IFNs inhibits HIV-1 replication (37, 76, 80-82). Different ISGs have been 
identified with varying anti-HIV-1 potency and it is assumed that the overall viral inhibition is a 
sum of the activities of individual ISGs. However, it has not been determined to what extent each 
of these ISGs contribute to the observed antiviral state. In chapter 3, I showed that mutations in 
critical residues (Tmut) in Vpu critical for tetherin antagonism reduce the production and release 
of virions by approximately 50% in the presence of IFNα2. In addition, Tmut chronic viruses were 
released 3-fold less efficiently than Tmut TF viruses. Consistent with my observations in Chapter 
2, I found that TF viruses were released more efficiently from CD4+ cells than chronic control 
viruses. Intriguingly, this finding was independent of the presence of Vpu, with TF viruses lacking 
Vpu released more efficiently than chronic viruses lacking Vpu. This suggests that other viral 
proteins can influence release independently of the Vpu- tetherin interaction. In this study, I also 
found that a Group N virus was very sensitive to IFNα2, and was released ~30% less efficiently 
than TF viruses in the presence of IFN, comparable to chronic viruses. Interestingly, the Group N 
Vpu promoted viral replication independent of its modest antagonism of tetherin. In the absence 
of IFNα2, Tmut viruses had similar levels of replication and particle release as wildtype viruses, 
and both (wildtype and Tmut) replicated to higher titers than viruses lacking Vpu. This suggests 
that functions of Vpu other than counteracting tetherin, such as the degradation of CD4 or the 
inhibition of NFkB mediated signaling might impact viral replication in primary cells.  
 
The observation that TF viruses are released more efficiently from infected cells deserves 
additional investigation. It is possible that TF viruses combine the ability to infect more target cells 
and higher burst sizes and thus have a higher reproductive ratio (R0) than viruses from chronic 
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infection (83). To specifically dissect this, one would need to determine the number of infected 
cells after a given number of cycles of replication, and then determine the number of infectious 
particles produced per infected cell after the addition of a fusion inhibitor to prevent subsequent 
rounds of infection. It will also be important to determine which viral protein (s) that contribute to 
this phenotype and what role they play. The observation that Vpu- deficient TF strains are 
released more efficiently than Vpu-deficient chronic strains implicates non-Vpu proteins. This 
property might be due to differences in protein function between TF and chronic viruses. 
Alternatively, non-coding regions like transcription factor binding sites, especially the NFkB 
binding sites in the long terminal repeat (LTR) can influence viral replication (84-86). The 
observation that Tmut TF strains are still released more efficiently than Tmut chronic viral strains 
suggest that this is independent of tetherin, but that there are differences in Vpu function between 
TF and chronic viruses. CD4 interacts with newly synthesized viral Env glycoprotein in the 
endoplasmic reticulum and has been shown to inhibit virus release and reduce virion infectivity 
(87-93). Other cellular proteins like T-cell immunoglobulin and mucin domain proteins can also 
affect virion release efficiency (94) and it would be interesting to assess if any of these are more 
effectively overcome by TF viruses.  
 
I observed that TF viruses were released more efficiently in the presence of IFNα2 than 
chronic viruses. As mentioned above, multiple cellular factors can affect and influence the 
measurements of particle release in our assay. However, it is tempting to speculate that TF 
viruses overcome tetherin-mediated restriction more efficiently than chronic viruses. A previous 
report compared the ability of TF and chronic Vpu alleles to downmodulate surface tetherin and 
promote viral release and did not find significant differences (95). However, these experiments 
were performed in cell lines using transient transfections. It is possible that more physiologically 
relevant levels of tetherin such as those observed in primary cells, and of Vpu expressed in the 
context of a full-length virus enable the observation of differences in activity. An alternative 
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possibility is that TF viruses have evolved another viral protein to counteract tetherin in addition to 
Vpu. A recent study found that certain HIV-1 group M viruses encoded Nef proteins with anti-
tetherin activity (96). Similarly, HIV-1 group O viruses, including the most recent common 
ancestor of the group O viruses, have been demonstrated to encode Nef proteins with anti-
tetherin activity (97). Thus, it is possible that TF Nef proteins are capable of overcoming tetherin 
in addition to their Vpu proteins allowing more efficient particle release. Vpu has been 
demonstrated to downmodulate NFkB activity (85), thus reducing the induction of antiviral genes. 
It is possible, that in addition to overcoming tetherin more efficiently, TF Vpu proteins inhibit NFkB 
activation more efficiently than chronic viruses.  
 
It would be extremely interesting to map the viral determinants of IFN resistance. To do 
this, one would require a panel of viruses that differ at very few nucleotide positions but differed 
greatly in their resistance to IFN. I assembled a panel of such virus clones from longitudinally 
followed individuals (n=13). These clones represented the TF virus and the consensus virus 
present six months following infection. Thus, the virus pairs from an individual were related 
genetically, and thus did not differ at too many positions across the genome (6-20 nucleotides). I 
demonstrated that the TF virus in each case was more resistant to IFN than the corresponding 
virus at 6-months, and in some cases this difference was up to 10-fold.  I constructed chimeric 
viruses by swapping regions of the genome between the IFN resistant TF and the sensitive 6-
month virus and used site-directed mutagenesis to identify specific amino acid residues that 
confer IFN sensitivity to TF viruses. It will be very interesting to continue this analysis and extend 
the identification of sensitivity-conferring mutations to all the virus pairs. Initial analysis did not 
identify common polymorphisms in all 13 IFN sensitive 6-month viruses, thus the determinants of 
IFN sensitivity are likely to be complex and multi-factorial.  
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Complimentary to the identification of the viral determinants, it would be interesting to 
assess the contribution of known anti-HIV-1 ISGs to the IFN-mediated antiviral state. In fact, once 
we identify the mutations responsible for conferring IFN sensitivity to the 6-month virus, I propose 
to use tools like mass spectrometry and proteomic analysis (in collaboration with Nevan Krogan) 
to determine whether TF and mutant viruses bind ISGs with different efficiencies, or whether 
mutant viruses are unable to interact with the ISG. These analyses will identify both viral 
mutations that cause sensitivity to IFN and determine which ISGs are responsible for the 
observed sensitivity of the 6-month virus. These experiments can be followed by studies like 
Chapter 3 to identify the contribution of other ISGs like A3G, MxB and IFITM to the restriction of 
viral replication observed in IFN- treated primary cells. It would be interesting to silence these 
host genes in primary target cells and assess the effect of IFN in restricting replication.  These 
experiments will enable the description of the key ISGs responsible for HIV-1 restriction in IFN-
stimulated primary CD4+ T cells.  
 
Thus, in summary, tetherin is clearly an important part of the anti-HIV-1 IFNα2 response, 
and it is intriguing that Group M viruses with adaptions at key anti-tetherin residues of Vpu have 
spread successfully in humans, while viruses with suboptimal adaptations like group N viruses 
have had limited spread. Additionally, TF viruses are released efficiently from infected cells. This 
is consistent with observations that initial small foci of infection rapidly result in millions of infected 
cells in acutely infected individuals. The efficient particle release from infected cells could explain 
these observations and the observed high R0 in acute infection. Lastly, the observation that TF 
viruses are released efficiently could provide evidence for the cell-free virus that initiates infection. 
Conversely, this could mean that chronic viruses are better at navigating cell-cell spread as 
previous reports suggest that tetherin-mediated restriction could enhance cell-cell spread.  
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